日本臨牀　別冊　呼吸器症候群（第3版）　IV

出版社： 日本臨牀社
発行日： 2021-11-30
分野： 臨床医学：一般  >  雑誌
ISSN： 00471852
雑誌名：
特集： 呼吸器症候群（第3版）　IV
電子書籍版： 2021-11-30 （第3版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

22,000 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

22,000 円(税込)

購入する

目次

  • 表紙
  • 目次
  • No. 17 呼吸器症候群 ( 第3版 ) I 内容項目一覧
  • No. 18 呼吸器症候群 ( 第3版 ) II 内容項目一覧
  • No. 19 呼吸器症候群 ( 第3版 ) III 内容項目一覧
  • No. 21 呼吸器症候群 ( 第3版 ) V 内容項目一覧
  • 序文 : 呼吸器症候群 ( 第3版 ) の発刊にあたって
  • IX 呼吸器感染症
  • 1. 細菌感染症
  • (1) MRSA感染症
  • (2) Streptococcus anginosus groupによる呼吸器感染症
  • (3) グラム陰性細菌による肺炎
  • (4) グラム陽性細菌による肺炎
  • (5) クレブシエラ肺炎 ( 肺炎桿菌肺炎 )
  • (6) 嫌気性菌肺炎
  • (7) 肺炎球菌性肺炎
  • (8) 肺化膿症 ( 肺膿瘍 )
  • (9) 百日咳
  • (10) ブドウ球菌性肺炎
  • (11) ヘモフィルス肺炎 ( インフルエンザ菌肺炎 )
  • (12) モラクセラ・カタラーリス肺炎
  • (13) レジオネラ肺炎
  • (14) レンサ球菌性肺炎 ( 肺炎球菌以外のレンサ球菌を主体に )
  • 2. 抗酸菌感染症
  • (1) 気管支結核
  • (2) リンパ節結核
  • (3) 結核腫
  • (4) 粟粒結核
  • (5) Mycobacterium kansasii症
  • (6) 肺 Mycobacterium avium complex ( MAC ) 症
  • (7) 肺結核
  • (8) その他の非結核性抗酸菌症
  • (9) 肺 Mycobacterium abscessus species症
  • (10) 潜在性結核感染症
  • 3. ウイルス感染症
  • (1) インフルエンザ肺炎・パラインフルエンザ肺炎
  • (2) 新型インフルエンザ
  • (3) 新型コロナウイルス感染症
  • (4) かぜ症候群 ( 上気道炎 )
  • (5) サイトメガロウイルス肺炎
  • (6) 重症急性呼吸器症候群 ( SARS )
  • (7) ヘルペス肺炎, 水痘肺炎
  • (8) 麻疹肺炎
  • 4. 真菌感染症
  • (1) 慢性肺アスペルギルス症
  • (2) 侵襲性肺アスペルギルス症
  • (3) ニューモシスチス肺炎
  • (4) 肺カンジダ感染症
  • (5) 肺クリプトコックス症
  • (6) 肺トリコスポロン症
  • (7) 肺ムーコル症 ( 接合菌症 )
  • 5. 原虫感染症
  • (1) クリプトスポリジウム症
  • (2) 赤痢アメーバ症
  • (3) トキソプラズマ症
  • (4) マラリア
  • (5) リーシュマニア症
  • 6. 寄生虫感染症 ( 肺蠕虫症 )
  • (1) イヌ回虫症
  • (2) イヌ糸状虫症
  • (3) 芽殖孤虫症
  • (4) 肺吸虫症
  • (5) 糞線虫症
  • (6) 有鉤嚢虫症
  • (7) エキノコックス症
  • 7 その他の病原体による感染症
  • (1) 気管支放線菌症肺放線菌症
  • (2) クラミジア・ニューモニエ肺炎
  • (3) 肺ノカルジア症
  • (4) マイコプラズマ肺炎
  • (5) リケッチア肺炎 ( つつが虫病, 日本紅斑熱, Q熱 )
  • 8 人畜 ( 人獣 ) 共通感染症
  • (1) ペスト
  • (2) パスツレラ肺炎
  • (3) 野兎病 ( 特に呼吸器型について )
  • (4) ブルセラ肺炎
  • 9. 感染症関連病態
  • (1) Mendelson症候群 ( acid aspiration pneumonia )
  • (2) Wandering Pneumonia
  • (3) HIV感染症およびAIDS患者の肺病変
  • (4) 外因性リポイド肺炎
  • (5) 器質化肺炎
  • (6) 高齢者肺炎
  • (7) 誤嚥性肺炎
  • (8) 市中肺炎と院内肺炎
  • (9) 人工呼吸器関連肺炎
  • (10) 中葉症候群 ( 舌区症候群 )
  • (11) 抗菌薬不応性肺炎
  • (12) 非定型肺炎・異型肺炎
  • (13) 日和見感染症
  • (14) 閉塞性肺炎
  • (15) 無気肺
  • (16) 免疫再構築症候群
  • 索引
  • 奥付

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

IX 呼吸器感染症

P.8 掲載の参考文献
1) 厚生労働省院内感染対策サーベイランス事業 : 公開情報2019年1月～12月年報 (全集計対象医療機関) 院内感染対策サーベイランス全入院患者部門. [https://janismhlw.go.jp/report/open_report/2019/3/2/zen_Open_Report_201900.pdf]
 
2) Watanabe A, et al : Multicenter survey on hospital-acquired pneumonia and the clinical efficacy of first-line antibiotics in Japan. Intern Med 47 : 245-254, 2008.
PubMed
3) 厚生労働省院内感染対策サーベイランス事業 : 公開情報 2019年1月～12月年報 院内感染対策サーベイランス 集中治療室部門. [https://janis.mhlw.go.jp/report/open_report/2019/3/3/ICU_Open_Report_201900.pdf]
 
4) Luyt CE, et al : Microbial cause of ICU-acquired pneumonia : hospital-acquired pneumonia versus ventilator-associated pneumonia. Curr Opin Crit Care 24 : 332-338, 2018.
PubMed
5) Chastre J, Fagon JY : Ventilator-associated pneumonia. Am J Respir Crit Care Med 165 : 867-903, 2002.
PubMed
6) Kaku N, et al : Molecular characteristics of methicillin-resistant Staphyloococcus aureus isolated from skin and soft tissue infections collected in the Japanese nationwide surveillance. J Dermatol 46 : 1205-1209, 2019.
 
7) Kaku N, et al : Influence of antimicrobial regimen on decreased in-hospital mortality of patients with MRSA bacteremia. J Infect Chemother 20 : 350-355, 2014.
PubMed
8) Iwanaga N, et al : Necrotizing pneumonia due to femoral osteomyelitis caused by community-acquired methicillin-resistant Staphylococcus aureus. Intern Med 52 : 1531-1536, 2013.
PubMed
9) 日本化学療法学会・日本感染症学会 : a. 呼吸器感染症. MRSA感染症の治療ガイドライン改訂版 2019 (MRSA感染症の治療ガイドライン作成委員会編), p34-40, 日本化学療法学会・日本感染症学会, 2019.
 
10) Morinaga Y, et al : Active Surveillance of Methicillin-Resistant Staphylococcus aureus Using a Fully Automated Molecular Test in an Emergency Medical Center. Jpn J Infect Dis 68 : 376-380, 2015.
 
11) 日本呼吸器学会 : CQ19 HAP/NHCAP治療において, 耐性菌感染が疑われる場合, 多剤耐性菌をカバーする初期治療は推奨されるか. 成人肺炎診療ガイドライン 2017 (日本呼吸器学会 成人肺炎診療ガイドライン2017作成委員会編), p129-134, 日本呼吸器学会, 2017.
 
12) Kalil AC, et al : Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia : 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 63 : e61-e111, 2016.
 
13) Jung YJ, et al : Effect of vancomycin plus rifampicin in the treatment of nosocomial methicillin-resistant Staphylococcus aureus pneumonia. Crit Care Med 38 : 175-180, 2010.
PubMed
P.12 掲載の参考文献
1) Okada F, et al : High-resolution CT findings in Streptococcus milleri pulmonary infection. Clin Radiol 68 : e331-337, 2013.
PubMed
2) Porta G, et al : Thoracic infection caused by Streptococcus milleri. Eur Respir J 12 : 357-362, 1998.
PubMed
3) Noguchi S, et al : The clinical features of respiratory infections caused by the Streptococcus anginosus group. BMC Pulm Med 15 : 133, 2015.
PubMed
4) Al Majid F, et al : Streptococcus anginosus group infections : Management and outcome at a tertiary care hospital. J Infect Public Health 13 : 1749-1754, 2020.
 
5) Ahmed RA, et al : Thoracic empyema in patients with community-acquired pneumonia. Am J Med 119 : 877-883, 2006.
PubMed
6) Wong CA, et al : Streptococcus milleri pulmonary disease : a review and clinical description of 25 patients. Thorax 50 : 1093-1096, 1995.
PubMed
7) Molina JM, et al : Clinical and bacterial features of infections caused by Streptococcus milleri. Scand J Infect Dis 23 : 659-666, 1991.
PubMed
8) Hocken DB, et al : Streptococcus milleri as a cause of pleural empyema. Thorax 40 : 626-628, 1985.
PubMed
9) Shinzato T, et al : A mechanism of pathogenicity of "Streptococcus milleri group" in pulmonary infection : synergy with an anaerobe. J Med Microbiol 40 : 118-123, 1994.
PubMed
10) Nagamune H, et al : Intermedilysin, a novel cytotoxin specific for human cells secreted by Streptococcus intermedius UNS46 isolated from a human liver abscess. Infect Immun 64 : 3093-3100, 1996.
PubMed
11) Toyoda K, et al : Pathogenicity of the Streptococcus milleri group in pulmonary infections--effect on phagocytic killing by human polymorphonuclear neutrophils. Kansenshogaku Zasshi 69 : 308-315, 1995.
PubMed
12) Tracy M, et al : Antibiotic susceptibilities of genetically characterized Streptococcus milleri group strains. Antimicrob Agents Chemother 45 : 1511-1514, 2001.
PubMed
13) Ripley RT, et al : Streptococcus milleri infections of the pleural space : operative management predominates. Am J Surg 192 : 817-821, 2006.
PubMed
P.17 掲載の参考文献
1) Falagas ME, et al : Attributable mortality of Stenotrophomonas maltophilia infections : a systematic review of the literature. Future Microbiol 4 : 1103-1109, 2009.
PubMed
2) Murphy TF, et al : Moraxella catarrhalis in chronic obstructive pulmonary disease : burden of disease and immune response. Am J Respir Crit Care Med 172 : 195-199, 2005.
PubMed
P.21 掲載の参考文献
1) 各論1市中肺炎. 成人肺炎診療ガイドライン 2017 (日本呼吸器学会成人肺炎診療ガイドライン2017作成委員会編), p9-33, 一般社団法人日本呼吸器学会, 2017.
 
2) Yamasaki K, et al : Significance of anaerobes and oral bacteria in community-acquired pneumonia. PLoS One 8 : e63103, 2013.
PubMed
3) 各論2院内肺炎/医療・介護関連肺炎. 成人肺炎診療ガイドライン 2017 (日本呼吸器学会成人肺炎診療ガイドライン2017作成委員会編), p34-48, 一般社団法人日本呼吸器学会, 2017.
 
4) Akata K, et al : The significance of oral streptococci in patients with pneumonia with risk factors for aspiration : the bacterial floral analysis of 16S ribosomal RNA gene using bronchoalveolar lavage fluid. BMC Pulm Med 16 : 79, 2016.
PubMed
5) Yatera K, et al : Determining the Possible Etiology of Hospital-Acquired Pneumonia Using a Clone Library Analysis in Japan. Tohoku J Exp Med 242 : 9-17, 2017.
PubMed
6) Yang K, et al : Corynebacteria as a cause of pulmonary infection : a case series and literature review. Pneumonia (Nathan) 10 : 10, 2018.
PubMed
7) Yatera K, Mukae H : Corynebacterium species as one of the major causative pathogens of bacterial pneumonia. Respir Investig 58 : 131-133, 2020.
PubMed
8) Li F, et al : Vancomycin-resistant Enterococcus faecium pneulnonia in a uremic patient on hemodialysis : a case report and review of the literature. BMC Infect Dis 20 : 167, 2020.
 
9) Kawanami T, et al : Clinical impact of methicillin-resistant staphylococcus aureus on bacterial pneumonia : cultivation and 16S ribosomal RNA gene analysis of bronchoalveolar lavage fluid. BMC Infect Dis 16 : 155, 2016.
PubMed
P.26 掲載の参考文献
1) Keynan Y, Rubinstein E : The changing face of Klebsiella pneumoniae infections in the community. Int J Antimicrob Agents 30 : 385-389, 2007.
PubMed
2) 厚生労働省 : 令和元年 (2019) 人口動態統計月報年計 (概数) の概況. [https://www.mhlw.go.jp/toukei/saikin/hw/jinkou/geppo/nengai19/dl/gaikyouR1.pdf]
 
3) Shindo Y, et al : Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia. Am J Respir Crit Care Med 188 : 985-995, 2013.
PubMed
4) Ko WC, et al : Community-Acquired Klebsiella pneumoniae Bacteremia : Global Differences in Clinical Patterns. Emerg Infect Dis 8 : 160-166, 2002.
PubMed
5) Liu YC, et al : Klebsiella pneumoniae liver abscess associated with septic endophthalmitis. Arch Intern Med 146 : 1913-1916, 1986.
PubMed
6) Zhu J, et al : Virulence Factors in Hypervirulent Klebsiella pneumoniae. Front Microbiol 12 : 642484, 2021.
PubMed
7) Ito R, et al : Molecular epidemiological characteristics of Klebsiella pneumoniae associated with bacteremia among patients with pneumonia. J Clin Microbiol 53 : 879-886, 2015.
PubMed
8) Catalan-Najera JC, et al : Hypervirulence and hypermucoviscosity : Two different but complementary Klebsiella spp. phenotypes? Virulence 8 : 1111-1123, 2017.
PubMed
9) Munoz-Price LS, et al : Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 13 : 785-796, 2013.
PubMed
10) Kaiser RM, et al : Trends in Klebsiella pneumoniae carbapenemase-positive K. pneumoniae in US hospitals : report from the 2007-2009 SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 76 : 356-360, 2013.
PubMed
11) Tang M, et al : Epidemiological Characteristics and Formation Mechanisms of Multidrug-Resistant Hypervirulent Klebsiella pneumoniae. Front Microbiol 11 : 581543, 2020.
PubMed
12) Yonekawa S, et al : Molecular and Epidemiological Characteristics of Carbapenemase-Producing Klebsiella pneumoniae Clinical Isolates in Japan. mSphere 5 : 2020.
PubMed
13) Cilloniz C, et al : Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax 66 : 340-346, 2011.
PubMed
14) Metlay JP, et al : Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 200 : e45-e67, 2019.
 
15) Kalil AC, et al : Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia : 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 63 : e61-e111, 2016.
 
P.31 掲載の参考文献
1) 日本臨床微生物学会 : 嫌気性菌検査ガイドライン 2012. 日本臨床微生物学会雑誌 22 (Suppl 1) : 1-142, 2012.
 
2) 浅井信博, 三鴨廣繁 : 嫌気性菌感染症. 日本内科学会雑誌 107 : 2282-2289, 2018.
 
3) O'Dwyer DN, et al : Lung Microbiota Contribute to Pulmonary Inflammation and Disease Progression in Pulmonary Fibrosis. Am J Respir Crit Care Med 199 : 1127-1138, 2019.
 
4) Huang YJ, et al : Airway microbiota and bronchial hyperresponsiveness in patients with suboptimally controlled asthma. J Allergy Clin Immunol 127 : 372-381.e1-3, 2011.
 
5) Mayhew D, et al : Longitudinal profiling of the lung microbiome in the AERIS study demonstrates repeatability of bacterial and eosinophilic COPD exacerbations. Thorax 73 : 422-430, 2018.
PubMed
6) Zheng L, et al : Lung microbiome alterations in NSCLC patients. Sci Rep 11 : 11736, 2021.
PubMed
7) 成人肺炎診療ガイドライン 2017 (日本呼吸器学会成人肺炎診療ガイドライン2017作成委員会編), p9, 日本呼吸器学会, 2017.
 
8) Matsunuma R, et al : I-ROAD could be efficient in predicting severity of community-acquired pneumonia or healthcare-associated pneumonia. Singapore Med J 55 : 318-324, 2014.
PubMed
9) Asai N, et al : Efficacy and accuracy of qSOFA and SOFA scores as prognostic tools for community-acquired and healthcare-associated pneumonia. Int J Infect Dis 84 : 89-96, 2019.
PubMed
10) Mukae H, et al : The Importance of Obligate Anaerobes and the Streptococcus anginosus Group in Pulmonary Abscess : A Clone Library Analysis Using Bronchoalveolar Lavage Fluid. Respiration 92 : 80-89t 2016.
PubMed
11) Akata K, et al : The significance of oral streptococci in patients with pneumonia with risk factors for aspiration : the bacterial floral analysis of 16S ribosomal RNA gene using bronchoalveolar lavage fluid. BMC Pulm Med 16 : 79, 2016.
PubMed
12) Asai N, et al : Ceftriaxone versus Tazobactam/Piperacillin and Carbapenems in the treatment of aspiration pneumonia : A Propensity Score Matching analysis. J Infect Chemother 27 : 1465-1470, 2021.
PubMed
13) Podglajen I, et al : Insertion of a novel DNA sequence, 1S1186, upstream of the silent carbapenemase gene cfiA, promotes expression of carbapenem resistance in clinical isolates of Bacteroides fragilis. Mol Microbiol 12 : 105-114, 1994.
PubMed
14) 山田敦子, ほか : カルバペネム系薬耐性Bacteroides属に関する疫学解析. 日本外科感染症学会雑誌 10 : 277-282, 2013.
Medical*Online
15) Eitel Z, et al : The prevalence of antibiotic resistance genes in Bacteroides fragilis group strains isolated in different European countries. Anaerobe 21 : 43-49, 2013.
PubMed
16) Husain F, et al : Two multidrug-resistant clinical isolates of Bacteroides fragilis carry a novel metronidazole resistance nim gene (nimJ). Antimicrob Agents Chemother 57 : 3767-3774, 2013.
PubMed
P.35 掲載の参考文献
1) Hussain M, et al : A longitudinal household study of Streptococcus pneumoniae nasopharyngeal carriage in a UK setting. Epidemiol Infect 133 : 891-898, 2005.
 
2) 成人肺炎診療ガイドライン 2017 (日本呼吸器学会成人肺炎診療ガイドライン2017作成委員会編), 一般社団法人日本呼吸器学会, 2017.
 
3) Fukusumi M, et al : Invasive pneumococcal disease among adults in Japan, April 2013 to March 2015 : disease characteristics and serotype distribution. BMC Infect Dis 17 : 2, 2017.
 
4) Janoff EN, Musher DM : Streptococcus pneumoniae. In : Manrell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 9th ed (ed by Bennet JE, et al), p2473-2491, Elsevier, Philadelphia, 2019.
 
5) Rodrigo C, et al : Pneumococcal serotypes in adult non-invasive and invasive pneumonia in relation to child contact and child vaccination status. Thorax 69 : 168-173, 2014.
PubMed
6) Del Rio-Pertuz G, et al : Usefulness of sputum gram stain for etiologic diagnosis in community-acquired pneumonia : a systematic review and meta-analysis. BMC Infect Dis 19 : 403, 2019.
 
7) Gutierrez F, et al : Evaluation of the immunochromatographic Binax NOW assay for detection of Streptococcus pneumoniae urinary antigen in a prospective study of community-acquired pneumonia in Spain. Clin Infect Dis 36 : 286-292, 2003.
 
8) Fukushima K, et al : Utility of a Sputum Antigen Detection Test in Pneumococcal Pneumonia and Lower Respiratory Infectious Disease in Adults. Intern Med 54 : 2843-2850, 2015.
PubMed
9) Haessler S, et al : Blood Cultures Versus Respiratory Cultures : 2 Different Views of Pneumonia. Clin Infect Dis 71 : 1604-1612, 2020.
PubMed
10) VII 呼吸器感染症. JAID/JSC感染症治療ガイド 2019 (JAID/JSC感染症治療ガイド・ガイドライン作成委員会編), 日本感染症学会/日本化学療法学会, 2019.
 
11) Yanagihara K, et al : Efficacy of azithromycin in the treatment of community-acquired pneumonia, including patients with macrolide-resistant Streptococcus pneumoniae infection. Intern Med 48 : 527-535, 2009.
PubMed
12) Baddour LM, et al : Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 170 : 440-444, 2004.
PubMed
13) Maruyama T, et al : Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents : double blind, randomised and placebo controlled trial. BMJ 340 : c1004, 2010.
PubMed
14) Kawakami K, et al : Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan. Vaccine 28 : 7063-7069, 2010.
PubMed
P.40 掲載の参考文献
1) Pennza PT : Aspiration pneumonia, necrotizing pneumonia, and lung abscess. Emerg Med Clin North Am 7 : 279-307, 1989.
PubMed
2) Penner C, et al : Pulmonary gangrene. A complication of bacterial pneumonia. Chest 105 : 567-573, 1994.
PubMed
3) 成人肺炎診療ガイドライン 2017 (日本呼吸器学会成人肺炎診療ガイドライン2017作成委員会編), 一般社団法人日本呼吸器学会, 2017.
 
4) Mohapatra MM, et al : Clinical, Radiological and Bacteriological Profile of Lung Abscess-An Observational Hospital Based Study. Open Access Maced J Med Sci 6 : 1642-1646, 2018.
PubMed
5) Moreira Jda S, et al : Lung abscess : analysis of 252 consecutive cases diagnosed between 1968 and 2004. J Bras Pneumol 32 : 136-143, 2006.
PubMed
6) Takayanagi N, et al : Etiology and outcome of community-acquired lung abscess. Respiration 80 : 98-105, 2010.
PubMed
7) McLoud TC, Flower CD : Imaging the pleura : sonography, CT, and MR imaging. AJR Am J Roentgenol 156 : 1145-1153, 1991.
 
8) Hassan M, et al : Lung abscess or empyema? Taking a closer look. Thorax 73 : 887-889, 20180
 
9) Gadkowski LB, Stout JE : Cavitary pulmonary disease. Clin Microbiol Rev 21 : 305-333, 2008.
PubMed
10) Gafoor K, et al : Cavitary Lung Diseases : A Clinical-Radiologic Algorithmic Approach. Chest 153 : 1443-1465, 2018.
PubMed
11) Kuhajda I, et al : Lung abscess-etiology, diagnostic and treatment options. Ann Transl Med 3 : 183, 2015.
PubMed
12) Egyud M, Suzuki K : Post-resection complications : abscesses, empyemas, bronchopleural fistulas. J Thorac Dis 10 (Suppl 28) : S3408-S3418, 2018.
 
13) Wali SO : An update on the drainage of pyogenic lung abscesses. Ann Thorac Med 7 : 3-7, 2012.
PubMed
14) Herth F, et al : Endoscopic drainage of lung abscesses : technique and outcome. Chest 127 : 1378-1381, 2005.
PubMed
15) Wang JL, et al : Changing bacteriology of adult community-acquired lung abscess in Taiwan : Klebsiella pneumoniae versus anaerobes. Clin Infect Dis 40 : 915-922, 2005.
PubMed
P.44 掲載の参考文献
1) Anderson RM, May RM : Directly transmitted infections diseases : control by vaccination. Science 215 : 1053-1060, 1982.
PubMed
2) 国立感染症研究所 : 百日咳 感染症法に基づく医師届出ガイドライン (初版), 平成30年4月25日. [https://www.niid.go.jp/niid/ja/pertussis-m/610-idsc/7994-pertussis-guideline-180425.html]
 
3) 国立感染症研究所 : 百日咳とは. (2018. 1. 29改訂) [https://www.niid.go.jp/niid/ja/kansennohanashi/477-pertussis.html」
 
4) 国立感染症研究所 : 2019年第1週から第52週までにNESIDに報告された百日咳患者のまとめ, 2019年第52週週報データ集計時点. [https://www.niid.go.jp/niid/images/epi/pertussis/pertussis-200306.pdf]
 
5) Liu BC, et al : Pertussis in older adults : prospective study of risk factors and morbidity. Clin Infect Dis 55 : 1450-1456, 2012.
PubMed
6) Cornia P, et al : Pertussis infection : Epidemiology, microbiology, and pathogenesis. In : UpToDate, Jun 2021. [https://www.uptodate.com/contents/pertussis-infection-epidemiology-microbiology-and-pathogenesis]
 
7) Yeh S, Mink CM : Pertussis infection in infants and children : Clinical features and diagnosis. In : UpToDate, Dec 2020. [https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-clinical-features-and-diagnosis?]
 
8) 永井文栄, 石和田稔彦 : 百日咳 ; 感染症呼吸器疾患. 細菌感染症. 別冊日本臨牀新領域別症候群シリーズ No. 8 呼吸器症候群 (第2版) I, p41-43, 日本臨牀社, 2008.
 
9) 咳嗽・喀痰の診療ガイドライン 2019 (日本呼吸器学会咳嗽・喀痰の診療ガイドライン2019作成委員会編), p33-37, 2019.
 
10) Centers for Disease Control and Prevention (CDC) : Pertussis (Whooping Cough). Surveillance and Reporting. [http://www.cdc.gov/pertussis/surv-reporting.html]
 
11) Siegel JD, et al : 2007 Guideline for Isolation Precautions : Preventing Transmission of Infectious Agents in Health Care Settings. Am J Infect Control 35 : S65-164, 2007.
PubMed
12) 香川大学における百日咳集団感染事例. IASR 29 : 68-69, 2008. [http://idsc.nih.go.jp/iasr/29/337/dj3372.html]
 
13) Nakamura K, et al : Pertussis outbreak among patients and healthcare workers in a provincial dialysis facility in Japan. J Hosp Infect 94 : 341-345, 2016.
 
14) Tiwari T, et al : National Immunization Program, CDC : Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis : 2005 CDC Guidelines. MMWR Recomm Rep 54 : 1-16, 2005. [https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5414a1.htm]
 
P.49 掲載の参考文献
1) 成人肺炎診療ガイドライン 2017 (日本呼吸器学会成人肺炎診療ガイドライン2017作成委員会編), 一般社団法人日本呼吸器学会, 2017.
 
2) Reed JC : Segmental and lobar densities. In : Chest Radiology. Plain Film Patterns and Differential Diagnosis, p149-160, Year Book Medical Publishing, Chicago, 1987.
 
3) Muller NL, et al : Bacterial pneumonia. In : Image of Pulmonary Infections (ed by Muller NL, et al), p20-55, Lippincott Williams & Wilkins, Philadelphia, 2007.
 
4) 永田正喜, ほか : 医療関連肺炎. 日本化学療法学会雑誌 60 : 188-192, 2012.
 
5) Piette A, Verschraegen G : Role of coagulase-negative staphylococci in human disease. Vet Microbiol 134 : 45-54, 2009.
PubMed
6) Cook RJ, et al : Septic pulmonary embolism : presenting features and clinical course of 14 patients. Chest 128 : 162-166, 2005.
PubMed
7) 永田正喜ほか : ベイズ解析を用いた診断確率定量によるMRSA下気道感染症診断の試み. 感染症学雑誌 84 : 276-284, 2010.
 
P.52 掲載の参考文献
1) Slack MPE : A review of the role of Haemophilus influenzae in community-acquired pneumonia. Pneumonia (Nathan) 6 : 26-43, 2015.
PubMed
2) 成人肺炎診療ガイドライン 2017 (日本呼吸器学会成人肺炎診療ガイドライン2017作成委員会編), 一般社団法人日本呼吸器学会, 2017.
 
3) Yamasaki K, et al : Significance of anaerobes and oral bacteria in community-acquired pneumonia. PLoS One 8 : e63103, 2013.
PubMed
4) Noguchi S, et al : Bacteriological assessment of healthcare-associated pneumonia using a clone library analysis. PLoS One 10 : e0124697, 2015.
PubMed
5) Yanagihara K, et al : Nationwide surveillance of bacterial respiratory pathogens conducted by the surveillance committee of Japanese Society of Chemotherapy, the Japanese Association for Infectious Diseases, and the Japanese Society for clinical microbiology in 2014 : General view of the pathogens' antibacterial susceptibility. J Infect Chemother 25 : 657-668, 2019.
PubMed
P.56 掲載の参考文献
1) Murphy TF, et al : Moraxella catarrhalis, a human respiratory tract pathogen. Clin Infect Dis 49 : 124-131, 2009.
PubMed
2) Morimoto K, et al : The burden and etiology of community-onset pneumonia in the aging Japanese population : a multicenter prospective study. PLoS One 10 : e0122247, 2015.
PubMed
3) Yamasaki K, et al : Significance of anaerobes and oral bacteria in community-acquired pneumonia. PLoS One 8 : e63103, 2013.
PubMed
4) Murphy TF, et al : Moraxella catarrhalis in chronic obstructive pulmonary disease : burden of disease and immune response. Am J Respir Crit Care Med 172 : 195-199, 2005.
PubMed
5) Hirai J, et al : Clinical characteristics of community-acquired pneumonia due to Moraxella catarrhalis in adults : a retrospective single-centre study. BMC Infect Dis 20 : 821, 2020.
PubMed
6) Johansson N, et al : Clinical impact of combined viral and bacterial infection in patients with community-acquired pneumonia. Scand J Infect Dis 43 : 609-615, 2011.
PubMed
7) Vaneechoutte M, et al : Respiratory tract carrier rates of Moraxella (Branhamella) catarrhalis in adults and children and interpretation of the isolation of M. catarrhalis from sputum. J Clin Microbiol 28 : 2674-2680, 1990.
PubMed
8) Maruyama T, et al : Community-acquired pneumonia and nursing home-acquired pneumonia in the very elderly patients. Respir Med 104 : 584-592, 2010.
PubMed
9) Oikawa J, et al : Changes in nasopharyngeal carriage of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis among healthy children attending a day-care centre before and after official financial support for the 7-valent pneumococcal conjugate vaccine and H. influenzae type b vaccine in Japan. J Infect Chemother 20 : 146-149, 2014.
 
10) Dunne EM, et al : Effect of pneumococcal vaccination on nasopharyngeal carriage of Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Staphylococcus aureus in Fijian children. J Clin Microbiol 50 : 1034-1038, 2012.
 
11) Su YC, et al : Moraxella catarrhalis : from interactions with the host immune system to vaccine development. Future Microbiol 7 : 1073-1100, 2012.
PubMed
12) DeMuri GP, et al : Dynamics of Bacterial Colonization With Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis During Symptomatic and Asymptomatic Viral Upper Respiratory Tract Infection. Clin Infect Dis 66 : 1045-1053, 2018.
PubMed
13) Munoz-Price LS, et al : Acinetobacter infection. N Engl J Med 358 : 1271-1281, 2008.
PubMed
14) Okada F, et al : Pulmonary thin-section CT findings in acute Moraxella catarrhalis pulmonary infection. Br J Radiol 84 : 1109-1114, 2011.
PubMed
15) Shi W, et al : β-Lactamase production and antibiotic susceptibility pattern of Moraxella catarrhalis isolates collected from two county hospitals in China. BMC Microbiol 18 : 77, 2018.
 
16) Yanagihara K, et al : Nationwide surveillance of bacterial respiratory pathogens conducted by the surveillance committee of japanese society of chemotherapy, the japanese association for infectious diseases, and the japanese society for clinical microbiology in 2016 : General view of the pathogens' antibacterial susceptibility. J Infect Chemother 26 : 873-881, 2020.
PubMed
17) 市中肺炎. 成人肺炎診療ガイドライン 2017 (日本呼吸器学会成人肺炎診療ガイドライン2017作成委員会編), p9-33, 一般社団法人日本呼吸器学会, 2017.
 
P.63 掲載の参考文献
1) Fraser DW, et al : Legionnaires' disease : Description of an epidemic of pneumonia. N Engl J Med 297 : 1189-1197, 1977.
PubMed
2) McDade JE, et al : Legionnaires' disease : isolation of a bacterium and demonstration of its role in other respiratory disease. N Engl J Med 297 : 1197-1203, 1977.
PubMed
3) 斎藤厚, ほか : 本邦ではじめてのLegionnaires' disease (レジオネラ症) の症例と検出菌の細菌学的性状. 感染症学雑誌 55 : 124-128, 1981.
 
4) Phin N, et al : Epidemiology and clinical management of Legionnaires' disease. Lancet Infect Dis 14 : 1011-1021, 2014.
PubMed
5) Arashiro T, et al : SARS-CoV-2 and Legionella co-infection in a person returning from a Nile cruise. J Travel Med 27 : 2020.
 
6) Chien M, et al : The genomic sequence of the accidental pathogen Legionella pneumophila. Science 305 : 1966-1968, 2004.
PubMed
7) Cazalet C, et al : Evidence in the Legionella pneumophila genome for exploitation of host cell functions and high genome plasticity. Nat Genet 36 : 1165-1173, 2004.
PubMed
8) Furugen M, et al : Legionella pneumophila infection induces programmed cell death, caspase activation, and release of high-mobility group box 1 protein in A549 alveolar epithelial cells : inhibition by methyl prednisolone. Respir Res 9 : 39, 2008.
PubMed
9) Edelstein PH, Roy CR : Legionella. In : Mandell, Douglas, and Bennetts' Principles and practice of infectious diseases 8th Edition (ed by Bennet JE, et al), p2633-2644, Elsevier Saunders, Philadelphia, 2014.
 
10) Miyashita N, et al : Clinical presentation of Legionella pneumonia : Evaluation of clinical scoring systems and therapeutic efficacy. J Infect Chemother 23 : 727-732, 2017.
PubMed
11) Miyashita N, et al : Distribution of Legionella species and serogroups in patients with cultureconfirmed Legionella pneumonia. J Infect Chemother 26 : 411-417, 2020.
 
12) Sakai F, et al : Computed tomographic features of Legionella pneumophila pneumonia in 38 cases. J Comput Assist Tomogr 31 : 125-131, 2007.
 
13) Yu H, et al : Computed tomographic features of 23 sporadic cases with Legionella pneumophila pneumonia. Eur J Radiol 74 : e73-78, 2010.
PubMed
14) Yu H, et al : Lung abscess caused by Legionella species : Implication of immune status of hosts. Intern Med 48 : 1997-2002, 2009.
PubMed
15) 新垣紀子, ほか : レジオネラ肺炎に対する早期診断法としての尿中抗原検出法の意義. 感染症学雑誌 73 : 421-428, 1999.
 
16) Ito A, et al : Evaluation of a novel urinary antigen test kit for diagnosing Legionella pneumonia. Int J Infect Dis 103 : 42-47, 2021.
PubMed
17) Koide M, Saito A : Diagnosis of Legionella pneumophila infection by polymerase chain reaction. Clin Infect Dis 21 : 199-201, 1995.
PubMed
18) 山口惠三, ほか : LAMP法を用いたMycoplasma pneumoniaeとLegionella spp. による呼吸器感染症の迅速診断試薬の評価. 医学と薬学 58 : 565-571, 2007.
Medical*Online
19) 斎藤厚 : レジオネラ症. 感染症の診断・治療ガイドライン 2004. 日本医師会雑誌 132 : 176-179, 2004.
 
20) Blazquez Garrido RM, et al : Antimicrobial chemotherapy for Legionnaires' disease : levofloxacin versus macrolides. Clin Infect Dis 40 : 800-806, 2005.
PubMed
21) Griffin AT, et al : Macrolides versus quinolones in Legionella pneumonia : results from the Community-Acquired Pneumonia Organization international study. Int J Tuberc Lung Dis 14 : 495-499, 2010.
 
22) Rello J, et al : Community-acquired Legionella Pneumonia in the intensive care unit : Impact on survival of combined antibiotic therapy. Med Intensiva 37 : 320-326, 2013.
PubMed
23) レジオネラ症防止指針編集委員会 : レジオネラ症防止指針 第4版. 公益財団法人日本建築衛生管理教育センター, 2017.
 
24) Tablan OC et al : Guidelines for preventing health-care-associated pneumonia, 2003 : recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm Rep 53 : 1-36, 2004.
PubMed
P.68 掲載の参考文献
1) Ferretti J, et al : History of Streptococcal Research. In : Streptococcus pyogenes : Basic Biology to Clinical Manifestations, University of Oklahoma Health Sciences Center, Oklahoma City, 2016.
PubMed
2) 成人肺炎診療ガイドライン 2017 (日本呼吸器学会成人肺炎診療ガイドライン2017作成委員会編), 一般社団法人日本呼吸器学会, 2017.
 
3) Carapetis JR, et al : The global burden of group A streptococcal diseases. Lancet Infect Dis 5 : 685-694, 2005.
 
4) Crum NF, et al : Pneumonia outbreak associated with group a Streptococcus species at a military training facility. Clin Infect Dis 40 : 511-518, 2005.
 
5) Stevens DL, Bryant AE : Necrotizing Soft-Tissue Infections. N Engl J Med 377 : 2253-2265, 2017.
PubMed
6) Tamayo E, et al : Streptococcus pyogenes Pneumonia in Adults : Clinical Presentation and Molecular Characterization of Isolates 2006-2015. PLoS One 11 : e0152640, 2016.
PubMed
7) Muller MP, et al : Clinical and epidemiologic features of group a streptococcal pneumonia in Ontario, Canada. Arch Intern Med 163 : 467-472, 2003.
 
8) Horn DL, et al : Why have group A streptococci remained susceptible to penicillin? Report on a symposium. Clin Infect Dis 26 : 1341-1345, 1998.
 
9) Francois Watkins LK, et al : Epidemiology of Invasive Group B Streptococcal Infections Among Nonpregnant Adults in the United States, 2008-2016. JAMA Intern Med 179 : 479-488, 2019.
PubMed
10) Farley MM : Group B streptococcal disease in nonpregnant adults. Clin Infect Dis 33 : 556-561, 2001.
 
11) Dahesh S, et al : Point mutation in the group B streptococcal pbp2x gene conferring decreased susceptibility to beta-lactam antibiotics. Antimicrob Agents Chemother 52 : 2915-2918, 2008.
 
12) Akata K, et al : The significance of oral streptococci in patients with pneumonia with risk factors for aspiration : the bacterial floral analysis of 16S ribosomal RNA gene using bronchoalveolar lavage fluid. BMC Pulm Med 16 : 79, 2016.
PubMed
13) Mukae H, et al : The Importance of Obligate Anaerobes and the Streptococcus anginosus Group in Pulmonary Abscess : A Clone Library Analysis Using Bronchoalveolar Lavage Fluid. Respiration 92 : 80-89, 2016.
PubMed
14) Nagashima H, et al : Abscess forming ability of streptococcus milleri group : synergistic effect with Fusobacterium nucleatum. Microbiol Immunol 43 : 207-216, 1999.
PubMed
15) Noguchi S, et al : The clinical features of respiratory infections caused by the Streptococcus anginosus group. BMC Pulm Med 15 : 133, 2015.
PubMed
P.73 掲載の参考文献
1) Jung SS, et al : Incidence and clinical predictors of endobronchial tuberculosis in patients with pulmonary tuberculosis. Respirology 20 : 488-495, 2015.
PubMed
2) 田村厚久, ほか : 気管支結核の現状 : 103例の解析. 結核 82 : 647-654, 2007.
 
3) 倉澤卓也 : もう一つの結核 : Endobronchial Tuberculosis. 結核 85 : 805-808, 2010
 
4) 岩井和郎 : 気管支結核. 図説・結核の病理 結核症の発病, 進展, 重症化の機序, p100-105, 公益財団法人結核予防会, 2012.
 
5) 岩崎龍郎 : VIII. 気管支の病変. 結核の病理, p127-136, 公益財団法人結核予防会 (保健同人ライブラリー 1. の復刻版), 1976.
 
6) Takasaki J, et al : A case of laryngeal and tracheobronchial tuberculosis presenting hoarseness and persistent cough. 20th Congress of the APSR, 2015.
 
7) 稲垣敬三, ほか : 気管気管支結核症-結核性気管気管支狭窄の治療を中心に-. 気管支学 23 : 368-374, 2001.
 
8) 三木啓資, ほか : 気管支結核症に対するINH (イソニアジド) 吸入療法の効果について. 日本呼吸器学会誌 37 : 31-35, 1999.
 
9) 力丸徹, 大泉耕太郎 : 気管支狭窄に対するストレプトマイシンとステロイド併用吸入療法の検討. 結核 74 : 879-888, 1999.
 
10) Mishra NR, et al : Corticosteroid as an Adjunct in the Treatment of Endobronchial Tuberculosis : A Systematic Review & Meta-analysis. Curr Pediatr Rev 16 : 53-60, 2020.
PubMed
P.77 掲載の参考文献
1) Grzybowski S, Allen EA : History and importance of scrofula. Lancet 346 : 1472-1474, 1995.
PubMed
2) Murray JF, et al : The King's Evil and the Royal Touch : the medical history of scrofula. Int J Tuberc Lung Dis 20 : 713-716, 2016.
 
3) Chan-Yeung M, et al : Sex differences in tuberculosis in Hong Kong. Int J Tuberc Lung Dis 6 : 11-18, 2002.
 
4) Temple SE, et al : Endotoxin induced TNF and IL-10 mRNA production is higher in male than female donors : correlation with elevated expression of TLR4. Cell Immunol 251 : 69-71, 2008.
PubMed
5) Wolf AJ, et al : Initiation of the adaptive immune response to Mycobacterium tuberculosis depends on antigen production in the local lymph node, not the lungs. J Exp Med 205 : 105-115, 2008.
 
6) Lin PL, et al : Sterilization of granulomas is common in active and latent tuberculosis despite within-host variability in bacterial killing. Nat Med 20 : 75-79, 2014.
PubMed
7) Ganchua SKC, et al : Lymph nodes are sites of prolonged bacterial persistence during Mycobacterium tuberculosis infection in macaques. PLoS Pathog 14 : e1007337, 2018.
PubMed
8) Diedrich CR, et al : SIV and Mycobacterium tuberculosis synergy within the granuloma accelerates the reactivation pattern of latent tuberculosis. PLoS Patho 916 : e1008413, 2020.
 
9) Havlir DV, Barnes PF : Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 340 : 367-373, 1999.
PubMed
10) Shriner KA, et al : Comparison of mycobacterial lymphadenitis among persons infected with human immunodeficiency virus and seronegative controls. Clin Infect Dis 15 : 601-605, 1992.
PubMed
11) Agarwal AK, et al : Tubercular cervical adenitis : clinicopathologic analysis of 180 cases. J Otolaryngol Head Neck Surg 38 : 521-525, 2009.
 
12) Artenstein AW, et al : Isolated peripheral tuberculous lymphadenitis in adults : current clinical and diagnostic issues. Clin Infect Dis 20 : 876-882, 1995.
PubMed
13) Blaikley JF, et al : Management of peripheral lymph node tuberculosis in routine practice : an unselected 10-year cohort. Int J Tuberc Lung Dis 15 : 375-378, 2011.
PubMed
14) Lau SK, et al : Efficacy of fine needle aspiration cytology in the diagnosis of tuberculous cervical lymphadenopathy. J Laryngol Otol 104 : 24-27, 1990.
 
15) Polesky A, et al : Peripheral tuberculous lymphadenitis : epidemiology, diagnosis, treatment, and outcome. Medicine (Baltimore) 84 : 350-362, 2005.
PubMed
16) Nahid P, et al : Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines : Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis 63 : e147-e195, 2016.
 
17) Turnbull L, et al : Tuberculosis (NICE clinical guideline 33). Arch Dis Child Educ Pract Ed 102 : 136-142, 2017.
PubMed
18) van Loenhout-Rooyackers JH, et al : Shortening the duration of treatment for cervical tuberculous lymphadenitis. Eur Respir J 15 : 192-195, 2000.
PubMed
19) Dartois V, Barry CE : Clinical pharmacology and lesion penetrating properties of second- and third-line antituberculous agents used in the management of multidrug-resistant (MDR) and extensively-drug resistant (XDR) tuberculosis. Curr Clin Pharmacol 5 : 96-114, 2010.
PubMed
20) Kislitsyna NA : [Comparative evaluation of rifampicin and isoniazid penetration into the pathological foci of the lungs in tuberculosis patients]. Probl Tuberk (4) : 55-57, 1985.
PubMed
21) Campbell IA, Dyson AJ : Lymph node tuberculosis : acomparison of treatments 18 months after completion of chemotherapy. Tubercle 60 : 95-98, 1979.
 
22) Jawahar MS, et al : Short course chemotherapy for tuberculous lymphadenitis in children. BMJ 301 : 359-362, 1990.
PubMed
23) Six-months versus nine-months chemotherapy for tuberculosis of lymph nodes : preliminary results. British Thoracic Society Research Committee. Respir Med 86 : 15-19, 1992.
PubMed
24) Yuen AP, et al : Prospective randomized study of thrice weekly six-month and nine-month chemotherapy for cervical tuberculous lymphadenopathy. Otolaryngol Head Neck Surg 116 : 189-192, 1997.
PubMed
25) Yu SN, et al : Late paradoxical lymph node enlargement during and after anti-tuberculosis treatment in non-HIV-infected patients. Int J Tuberc Lung Dis 19 : 1388-1394, 2015.
 
26) Park KH, et al : Incidence and outcomes of paradoxical lymph node enlargement after anti-tuberculosis therapy in non-HIV patients. J Infect 67 : 408-415, 2013.
PubMed
27) Mandell DL, et al : Management of nontuberculous mycobacterial cervical lymphadenitis. Arch Otolaryngol Head Neck Surg 129 : 341-344, 2003.
PubMed
P.82 掲載の参考文献
1) 公益財団法人結核研究所 : 新・結核用語辞典. [https://jata.or.jp/term.php]
 
2) 結核の統計 2020 (公益財団法人結核予防会編), 公益財団法人結核予防会, 2020.
 
3) 国立研究開発法人国立がん研究センターがん対策情報センター : がん種別統計情報 肺. [https://ganjoho.jp/reg_stat/statistics/stat/cancer/12_lung.html]
 
4) 日本結核・非結核性抗酸菌症学会教育・用語委員会 : 結核症の発生病理. 結核症の基礎知識 (改訂第5版), p95-97, 2021. [https://www.kekkaku.gr.jp/books-basic/pdf/1.pdf]
 
5) 尾形英雄 : 肺結核のCT画像と病理所見. 結核 84 : 559-568, 2009.
 
6) Takasaki J, et al : Sensitivity and specificity of QuantiFERON-TB Gold Plus compared with QuantiFERON-TB Gold In-Tube and T-SPOT. TB on active tuberculosis in Japan. J Infect Chemother 24 : 188-192, 2018.
 
7) 厚生労働省健康局 : 「結核医療の基準」の一部改正について. 平成30年4月18日. [https://www.mhlw.go.jp/file/06-Seisakujouhou-10900000-Kenkoukyoku/0000203934.pdf]
 
P.87 掲載の参考文献
1) Sharma SK, et al : Miliary tuberculosis : A new look at an old foe. J Clin Tuberc Other Mycobact Dis 3 : 13-27, 2016.
 
2) Iseman MD : Disseminated tuberculosis. In : A clinician's guide to tuberculosis, p167-173, Lippincott Williams & Wilkins, Philadelphia, 2000.
 
3) 公益財団法人結核予防会 : 結核の統計 2020, 公益財団法人結核予防会, 2020.
 
4) Sharma SK, et al : Miliary tuberculosis : new insights into an old disease. Lancet Infect Dis 5 : 415-430, 2005.
PubMed
5) Trunz BB, et al : Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide : a meta-analysis and assessment of cost-effectiveness. Lancet 367 : 1173-1180, 2006.
PubMed
6) Mert A, et al : Miliary tuberculosis : Epidemiologicaland clinical analysis of large-case series from moderate to low tuberculosis endemic Country. Medicine (Baltimore) 96 : e5875, 2017.
PubMed
7) Kwong JS, et al : Miliary tuberculosis. Diagnostic accuracy of chest radiography. Chest 110 : 339-342, 1996.
PubMed
8) Hong SI, et al : Is the sensitivity of the QuantiFERON-TB Gold In-Tube test lower than that of T-SPOT. TB in patients with miliary tuberculosis? Clin Infect Dis 59 : 142, 2014.
PubMed
9) Nahid P, et al : Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines : Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis 63 : e147-e195, 2016.
 
10) 日本結核病学会治療委員会 : 「結核医療の基準」の改訂-2018年. 結核 93 : 61-68, 2018.
Medical*Online
P.90 掲載の参考文献
1) Namkoong H, et al : Epidemiology of Pulmonary Nontuberculous Mycobacterial Disease, Japan. Emerg Infect Dis 22 : 1116-1117, 2016.
PubMed
2) Zweijpfenning SMH, et al : Geographic Distribution of Nontuberculous Mycobacteria Isolated from Clinical Specimens : A Systematic Review. Semin Respir Crit Care Med 39 : 336-342, 2018.
PubMed
3) Sakatani M : [The non-tuberculous mycobacteriosis]. Kekkaku 80 : 25-30, 2005.
PubMed
4) Morimoto K, et al : A Laboratory-based Analysis of Nontuberculous Mycobacterial Lung Disease in Japan from 2012 to 2013. Ann Am Thorac Soc 14 : 49-56, 2017.
PubMed
5) Kim JH, et al : Risk factors for developing Mycobacterium kansasii lung disease : A case-control study in Korea. Medicine (Baltimore) 98 : e14281, 2019.
 
6) Furuuchi K, et al : Interrelational changes in the epidemiology and clinical features of nontuberculous mycobacterial pulrnonary disease and tuberculosis in a referral hospital in Japan. Respir Med 152 : 74-80, 2019.
 
7) Shitrit D, et al : Pulmonary Mycobacterium kansasii infection in Israel, 1999-2004 : clinical features, drug susceptibility, and outcome. Chest 129 : 771-776, 2006.
PubMed
8) Daley CL, et al : Treatment of nontuberculous mycobacterial pulmonary disease : an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur Respir J 56 : 2000535, 2020.
PubMed
9) Sato R, et al : Interferon-gamma release assays in patients with Mycobacterium kansasii pulmonary infection : A retrospective survey. J Infect 72 : 706-712, 2016.
PubMed
10) 神宮浩之, ほか : Mycobacterium kansasii症の女性例の検討. 結核 83 : 73-79, 2008.
 
11) Shitrit D, et al : Differentiation of Mycobacterium kansasii infection from Mycobacterium tuberculosis infection : comparison of clinical features, radiological appearance, and outcome. Eur J Clin Microbiol Infect Dis 26 : 679-684, 2007.
PubMed
12) de Carvalho LD, et al : Drug susceptibility profile of Mycobacterium kansasii clinical isolates from Brazil. J Glob Antimicrob Resist 19 : 228-230, 2019.
 
13) Liu CJ, et al : Outcome of patients with and poor prognostic factors for Mycobacterium kansasii-pulmonary disease. Respir Med 151 : 19-26, 2019.
 
14) Griffith DE, et al : An Official ATS/IDSA Statement : Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases. Am J Rrespir Crit Care Med 175 : 367-416, 2007.
 
15) Naito M, et al : Prognosis of chronic pulmonary aspergillosis in patients with pulmonary nontuberculous mycobacterial disease. Respir Investig 56 : 326-331, 2018.
PubMed
P.94 掲載の参考文献
1) Boyle DP, et al : Comparison of Clinical Features, Virulence, and Relapse among Mycobacterium avium Complex Species. Am J Respir Crit Care Med 191 : 1310-1317, 2015.
PubMed
2) Namkoong H, et al : Epidemiology of Pulmonary Nontuberculous Mycobacterial Disease, Japan. Emerg Infect Dis 22 : 1116-1117, 2016.
PubMed
3) 日本結核病学会非結核性抗酸菌症対策委員会, 日本呼吸器学会感染症・結核学術部会 : 肺非結核性抗酸菌症診断に関する指針-2008年. 結核 83 : 525-526, 2008.
 
4) Griffith DE, et al : An official ATS/IDSA statement : diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 175 : 367-416, 2007.
PubMed
5) Daley CL, et al : Treatment of nontuberculous mycobacterial pulmonary disease : an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur Respir J 56 : 2000535, 2020.
PubMed
6) Kitada S, et al : Serodiagnosis of Mycobacterium avium-complex pulmonary disease using an enzyme immunoassay kit. Am J Respir Crit Care Med 177 : 793-797, 2008.
PubMed
7) 日本結核病学会非結核性抗酸菌症対策委員会, 日本呼吸器学会感染症・結核学術部会 : 肺非結核性抗酸菌症化学療法に関する見解-2012年改訂. 結核 87 : 83-86, 2012.
Medical*Online
8) Wallace RJ, et al : Macrolide/Azalide therapy for nodular/bronchiectatic mycobacterium avium complex lung disease. Chest 146 : 276-282, 2014.
PubMed
9) Jeong BH, et al : Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 191 : 96-103, 2015.
PubMed
10) Griffith DE, et al : Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study. Am J Respir Crit Care Med 198 : 1559-1569, 2018.
 
11) Koh WJ, et al : Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype. Eur Respir J 50 : 1602503, 2017.
PubMed
12) Furuuchi K, et al : Treatment Duration and Disease Recurrence Following the Successful Treatment of Patients With Mycobacterium avium Complex Lung Disease. Chest 157 : 1442-1445, 2020.
PubMed
13) Griffith DE, et al : Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 174 : 928-934, 2006.
PubMed
14) Morimoto K, et al : Macrolide-Resistant Mycobacterium avium Complex Lung Disease : Analysis of 102 Consecutive Cases. Ann Am Thorac Soc 13 : 1904-1911, 2016.
PubMed
15) 日本結核病学会非結核性抗酸菌症対策委員会 : 肺非結核性抗酸菌症に対する外科治療の指針. 結核 83 : 527-528, 2008.
 
P.102 掲載の参考文献
1) 結核の統計 2020 (公益財団法人結核予防会編), 公益財団法人結核予防会, 2020.
 
2) 斎藤肇 : 直接並びに集菌塗抹喀痰からの抗酸菌検出成績の比較. 第26回結核・非定型抗酸菌症治療研究会資料, 平成13年12月1日.
 
3) 抗酸菌検査ガイド 2020 (日本結核・非結核性抗酸菌症学会編), 南江堂, 2020.
 
4) 「結核医療の基準」の一部改正について. 健感発0418 第1号 平成30年4月18日.
 
5) 感染症法の予防及び感染症の患者に対する医療に関する法律. 平成28年4月1日改正.
 
6) Sekizuka T, et al : TGS-TB : Total Genotyping Solution for Mycobacterium tuberculosis Using Short-Read Whole-Genome Sequencing. PLoS One 10 : e0142951, 2015.
PubMed
7) V. 結核の治療. 結核診療ガイド (日本結核病学会編), p87-107, 南江堂, 2018.
 
8) Dorman SE, et al : Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. N Engl J Med 384 : 1705-1718, 2021.
 
9) WHO : WHO consolidated guidelines on tuberculosis, Module 4 : Treatment, Drug-resistant tuberculosis treatment, Geneva, 2020.
PubMed
10) Nahid P, et al : Treatment of drug-resistant tuberculosis. An official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Am J Respir Crit Care Med 200 : e93-el42, 2019.
PubMed
11) Fregonese F, et al : Comparison of different treatments for isoniazid-resistant tuberculosis : an individual patient data meta-analysis. Lancet Respir Med 6 : 265-275, 2018.
PubMed
12) Conradie F, et al : Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med 382 : 893-902, 2020.
PubMed
P.106 掲載の参考文献
1) 日本結核病学会非結核性抗酸菌症対策委員会, 日本呼吸器学会感染症・結核学術部会 : 肺非結核性抗酸菌症診断に関する指針-2008年. 結核 83 : 525-526, 2008.
 
2) 大楠清文 : 抗酸菌の同定. 抗酸菌検査ガイド 2020 (日本結核・非結核性抗酸菌症学会編), p47-70, 南江堂, 2020.
 
3) Morimoto K, et al : A Laboratory-based Analysis of Nontuberculoしls Mycobacterial Lung Disease in Japan from 2012 to 2013. Ann Am Thorac Soc 14 : 49-56, 2017.
 
4) Baldwin SL, et al : The complexities and challenges of preventing and treating nontuberculous mycobacterial diseases. PLoS Negl Trop Dis 13 : e00O7083, 2019.
PubMed
5) Gupta RS, et al : Phylogenomics and Comparative Genomic Studies Robustly Support Division of the Genus Mycobacterium into an Emended Genus Mycobacterium and Four Novel Genera. Front Microbiol 9 : 67, 2018.
PubMed
6) Griffith DE, et al : An official ATS/IDSA statement : diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 175 : 367-416, 2007.
PubMed
7) van Ingen J, et al : Are phylogenetic position, virulence, drug susceptibility and in vivo response to treatment in mycobacteria interrelated? Infect Genet Evol 12 : 832-837, 2012.
PubMed
8) Aono A, et al : Antimicrobial susceptibility testing of Mycobacteroides (Mycobacterium) abscessus complex, Mycolicibacterium (Mycobacterium) fortuitum, and Mycobacteroides (Mycobacterium) chelonae. J Infect Chemother 25 : 117-123, 2019.
PubMed
9) 倉島篤行 : 比較的稀な菌種による肺非結核性抗酸菌症の治療. 結核 86 : 923-932, 2011.
Medical*Online
10) 窪田綾子, ほか : Mycobacterium terraeによる呼吸器感染症の1例. 日本内科学会雑誌 107 : 2498-2504, 2018.
 
11) 澤幡美千瑠, ほか : 健康な若年男性に発症した肺Mycobacterium peregrinum感染症の1例. 日本呼吸器学会誌 48 : 866-870, 2010.
 
12) 江森幹子, ほか : Mycobacterium scrofulaceum肺感染症の15例. 結核 82 : 173-178, 2007.
 
13) 関根朗雅, ほか : Mycobacterium szulgai肺感染症の4例と本邦報告例の文献的考察. 日本呼吸器学会誌 46 : 880-888, 2008.
 
14) Haworth CS, et al : British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax 72 : ii1-ii64, 2007.
 
15) Varadi RG, Marras TK : Pulmonary Mycobacterium xenopi infection in non-HIV-infected patients : a systematic review. Int J Tuberc Lung Dis 13 : 1210-1218, 2009.
PubMed
P.112 掲載の参考文献
1) Daley CL, et al : Treatment of Nontuberculous Mycobacterial Pulmonary Disease : An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. Clin Infect Dis 71 : 905-913, 2020.
PubMed
2) Namkoong H, et al : Epidemiology of Pulmonary Nontuberculous Mycobacterial Disease, Japan. Emerg Infect Dis 22 : 1116-1117, 2016.
PubMed
3) Furuuchi K, et al : Interrelational changes in the epidemiology and clinical features of nontuberculous mycobacterial pulmonary disease and tuberculosis in a referral hospital in Japan. Respir Med 152 : 74-80, 2019.
 
4) Morimoto K, et al : A laboratory-based analysis of nontuberculous mycobacterial lung disease in Japan from 2012 to 2013. Ann Am Thorac Soc 14 : 49-56, 2017.
PubMed
5) Nagano H, et al : Causative species of nontuberculous mycobacterial lung disease and comparative investigation on clinical features of Mycobacterium abscessus complex disease : A retrospective analysis for two major hospitals in a subtropical region of Japan. PLoS One 12 : e0186826, 2017.
 
6) Simons S, et al : Nontuberculous mycobacteria in respiratory tract infections, eastern Asia. Emerg Infect Dis 17 : 343-349, 2011.
PubMed
7) Fujiwara K, et al : Clinical risk factors related to treatment failure in Mycobacterium abscessus lung disease. Eur J Clin Microbiol Infect Dis 40 : 247-254, 2021.
PubMed
8) Yoshida M, et al : A novel DNA chromatography method to discriminate Mycobacterium abscessus subspecies and macrolide susceptibility. EBioMedicine 64 : 103187, 2021.
 
9) Kobayashi T, et al : Serum immunoglobulin a antibodies to glycopeptidolipid core antigen for Mycobacteroides abscessus complex lung disease. Int J Mycobacteriol 9 : 76-82, 2020.
PubMed
10) Morimoto K, et al : Clinico-microbiological analysis of 121 patients with pulmonary Mycobacteroides abscessus complex disease in Japan-An NTM-JRC study with RIT. Respir Med 145 : 14-20, 2018.
 
11) Koh WJ, et al : Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med 183 : 405-410, 2011.
PubMed
12) Choi H, et al : Clinical Characteristics and Treatment Outcomes of Patients with Acquired Macrolide-Resistant Mycobacterium abscessus Lung Disease. Antimicrob Agents Cemother 61 : e01146-17, 2017.
PubMed
P.117 掲載の参考文献
1) 結核の統計 2020 (公益財団法人結核予防会編), 公益財団法人結核予防会, 2020.
 
2) 公益財団法人結核予防会結核研究所疫学情報センター : 結核の統計 月報. [https://www.jata.or.jp/rit/ekigaku/toukei/2/]
 
3) Landry J, Menzies D : Preventive chemotherapy. Where has it got us? Where to go next? Int J Tuberc Lung Dis 12 : 1352-1364, 2008.
PubMed
4) 日本結核病学会予防委員会・治療委員会 : 潜在性結核感染症治療指針. 結核 88 : 497-512, 2013.
Medical*Online
5) Sterling TR, et al : Guidelines for the treatment of latent tuberculosis infection : recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep 69 : 1-11, 2020.
PubMed
6) Getahun H, et al : Management of latent Mycobacterium tuberculosis infection : WHO guidelines for low tuberculosis burden countries. Eur Respir J 46 : 1563-1576, 2015.
PubMed
7) World Health Organization : Latent tuberculosis infection : updated and consolidated guideline for programmatic management, WHO, Geneva, 2018. [https://apps.who.int/iris/bitstream/handle/10665/260233/9789241550239-eng.pdf?sequence=1&isAllowed=y]
 
8) 日本結核病学会予防委員会・治療委員会 : 潜在性結核感染症治療レジメンの見直し. 結核 94 : 515-518, 2019.
Medical*Online
P.122 掲載の参考文献
1) Uyeki TM, et al : Clinical Practice Guidelines by the Infectious Diseases Society of America : 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa. Clin Infect Dis 68 : 895-902, 2019.
 
2) 関雅文 : インフルエンザウイルス肺炎. 日本医師会雑誌 134 : 1929-1932, 2006.
 
3) Seki M, et al : Disease severity in patients with simultaneous influenza and bacterial pneumonia. Intern Med 46 : 953-958, 2007.
PubMed
4) Seki M, et al : Immunokinetics in severe pneumonia due to influenza virus and bacteria coinfection in mice. Eur Respir J 24 : 143-149, 2004.
PubMed
5) パラインフルエンザ. 感染症専門医テキスト 第I部 解説編 [改訂第2版] (日本感染症学会編), p914-916, 南江堂, 2017.
 
6) 成人肺炎診療ガイドライン 2017 (日本呼吸器学会成人肺炎診療ガイドライン2017作成委員会編), 一般社団法人日本呼吸器学会, 2017.
 
7) 石黒卓, ほか : 成人市中肺炎におけるウィルス感染の関与-単一施設での前向き検討-. 日本呼吸器学会誌 49 : 10-19, 2011.
 
8) 関雅文 : インフルエンザ関連肺炎の診断・治療の動向-成人の新型インフルエンザ診療ガイドライン2014を踏まえて. 医学と薬学 72 : 825-830, 2015.
Medical*Online
9) 厚生労働省 : 新型コロナウイルス感染症 (COVID-19) 診療の手引き [第5版], 2021. [https://www.mhlw.go.jp/content/000785119.pdf]
 
10) Seki M, et al : Adult influenza A (H3N2) with reduced susceptibility to baloxavir or peramivir cured after switching anti-influenza agents. IDCases 18 : e00650, 2019.
 
11) 日本化学療法学会, ほか : 抗菌薬適正使用支援プログラム実践のためのガイダンス. 日本化学療法学会雑誌 65 : 650-687, 2017. [http://www.chemotherapy.or.jp/guideline/kobiseibutuyaku_guidance.pdf]
 
12) 日本感染症学会ワクチン委員会, ほか : 65歳以上の成人に対する肺炎球菌ワクチン接種に関する考え方 (第3版), 2019. [https://www.kansensho.or.jp/uploads/files/guidelines/065haienV/065haienV_191030.pdf]
 
13) 日本感染症学会ワクチン委員会, ほか : 6歳から64歳までのハイリスク者に対する肺炎球菌ワクチン接種の考え方, 2021. [https://www.jrs.or.jp/uploads/uploads/files/guidelines/haien_kangae20210520.pdf]
 
14) 日本感染症学会ワクチン委員会 : COVID-19ワクチンに関する提言 (第3版), 2021. [https://www.kansensho.or.jp/uploads/files/guidelines/2107_covid-19_3.pdf]
 
P.126 掲載の参考文献
1) McCauley JW, et al : Orthomyxoviridae. In : Virus Taxonomy : Ninth Report of the International Committee on Taxonomy of Viruses (ed by King AMQ, et al), p749-761, Elsevier, Academic Press, Waltham, MA, 2012.
 
2) Swayne DE, et al : Avian influenza. In : Diseases of Poultry, 13th ed (ed by Swayne DE, et al), p181-218, Wiley-Blackwell, Ames, IA, 2013.
 
3) van Reeth K, Vincent AL : Influenza viruses, In : Diseases of Swine, 11th ed (ed by Zimmerman JJ, et al), P576-593, John Wiley & Sons, Inc., Hoboken, NJ, 2019.
 
4) de Jong JC, et al : A pandemic warning? Nature 389 : 554, 1997.
PubMed
5) Smith GJ, et al : Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature 459 : 1122-1125, 2009.
PubMed
6) Centers for Disease Control and Prevention : Influenza Risk Assessment Tool (IRAT). [https://www.cdc.gov/flu/pandemic-resources/national-strategy/risk-assessment.htm]
 
7) World Health Organization : Influenza at the human-animal interface summary and assessment, 22 June 2021. [https://www.who.int/publications/m/item/influenza-at-the-human-animal-interface-summary-and-assessment-22-june-2021]
 
8) World Health Organization : Antigenic and genetic characteristics of zoonotic influenza A viruses and development of candidate vaccine viruses for pandemic preparedness. [https://www.who.int/influenza/vaccines/virus/202103_zoonotic_vaccinevirusupdate.pdf]
 
9) Gao HN, et al : Clinical findings in 111 cases of influenza A (H7N9) virus infection. N Engl J Med 368 : 2277-2285, 2013.
PubMed
10) Bai GR, et al : Improvement of a rapid diagnosis kit to detect either influenza A or B virus infections. J Vet Med Sci 68 : 35-40, 2006.
PubMed
11) Noshi T, et al : In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit. Antiviral Res 160 : 109-117, 2018.
PubMed
12) Jhung MA, et al : Outbreak of variant influenza A (H3N2) virus in the United States. Clin Infect Dis 57 : 1703-1712, 2013.
PubMed
P.136 掲載の参考文献
1) Isaacs D, et al : Epidemiology of coronavirus respiratory infections. Arch Dis Child 58 : 500-503, 1983.
PubMed
2) Gaunt ER, et al : Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method. J Clin Microbiol 48 : 2940-2947, 2010.
 
3) Monto AS : Medical reviews. Coronaviruses. Yale J Biol Med 47 : 234-251, 1974.
PubMed
4) Callow KA, et al : The time course of the immune response to experimental coronavirus infection of man. Epidemiol Infect 105 : 435-446, 1990.
PubMed
5) Zhu N, et al : A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med 382 : 727-733, 2020.
 
6) Hoffmann M, et al : SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 181 : 271-280.e8, 2020.
 
7) Matsuyama S, et al : Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc Natl Acad Sci U S A 117 : 7001-7003, 2020.
PubMed
8) Davies NG, et al : Estimated transmissibility and impact of SARS-CoV-21ineage B.1.1.7 in England. Science 372 : eabg3055, 2021.
PubMed
9) Challen R, et al : Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1 : matched cohort study. BMJ 372 : n579, 2021.
PubMed
10) Mahase E : Covid-19 : What new variants are emerging and how are they being investigated? BMJ 372 : n158, 2021.
PubMed
11) Madhi SA, et al : Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med 384 : 1885-1898, 2021.
 
12) Fujino T, et al : Novel SARS-CoV-2 Variant in Travelers from Brazil to Japan. Emerg Infect Dis 27 : 1243-1245, 2021.
 
13) Sheikh A, et al : SARS-CoV-2 Delta VOC in Scotland : demographics, risk of hospital admission, and vaccine effectiveness. Lancet 397 : 2461-2462, 2021.
PubMed
14) Li Q, et al : Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med 382 : 1199-1207, 2020.
PubMed
15) Guan WJ, et al : Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 382 : 1708-1720, 2020.
 
16) Kutsuna S, et al : SARS-CoV-2 Screening Test for Japanese Returnees From Wuhan, China, January 2020. Open Forum Infect Dis 7 : ofaa243, 2020.
PubMed
17) Oran DP, Topol EJ : The Proportion of SARS-CoV-2 Infections That Are Asymptomatic : A Systematic Review. Ann Intern Med 174 : 655-662, 2021.
PubMed
18) Kasper MR, et al : An Outbreak of Covid-19 on an Aircraft Carrier. N Engl J Med 383 : 2417-2426, 2020.
 
19) Stokes EK, et al : Coronavirus Disease 2019 Case Surveillance-United States, January 22-May 30, 2020. MMWR Morb Mortal Wkly Rep 69 : 759-765, 2020.
PubMed
20) Cheung KS, et al : Gastrointestinal Manifestations of SARS-CoV-2 Infection and Virus Load in Fecal Samples From a Hong Kong Cohort : Systematic Review and Meta-analysis. Gastroenterology 159 : 81-95, 2020.
PubMed
21) Tong JY, et al : The Prevalence of Olfactory and Gustatory Dysfunction in COVID-19 Patients : A Systematic Review and Meta-analysis. Otolaryngol Head Neck Surg 163 : 3-11, 2020.
PubMed
22) Cevik M, et al : Virology, transmission, and pathogenesis of SARS-CoV-2. BMJ 371 : m3862, 2020.
PubMed
23) Oxley TJ, et al : Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young. N Engl J Med 382 : e60, 2020.
 
24) Bangalore S, et al : ST-Segment Elevation in Patients with Covid-19-A Case Series. N Engl J Med 382 : 2478-2480, 2020.
PubMed
25) Ortega-Paz L, et al : Coronavirus Disease 2019-Associated Thrombosis and Coagulopathy : Review of the Pathophysiological Characteristics and Implications for Antithrombotic Management. J Am Heart Assoc 10 : e019650, 2021.
PubMed
26) Gupta A, et al : Extrapulmonary manifestations of COVID-19. Nat Med 26 : 1017-1032, 2020.
PubMed
27) Huang C, et al : Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395 : 497-506, 2020.
PubMed
28) Matsunaga N, et al : Clinical epidemiology of hospitalized patients with COVID-19 in Japan : Report of the COVID-19 REGISTRY JAPAN. Clin Infect Dis : ciaa1470, 2020.
 
29) He X, et al : Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med 26 : 672-675, 2020.
PubMed
30) Rhee C, et al : Duration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infectivity : When Is It Safe to Discontinue Isolation? Clin Infect Dis 72 : 1467-1474, 2021.
PubMed
31) Meyerowitz EA, et al : Transmission of SARS-CoV-2 : A Review of Viral, Host, and Environmental Factors. Ann Intern Med 174 : 69-79, 2021.
PubMed
32) Liang W, et al : Cancer patients in SARS-CoV-2 infection : a nationwide analysis in China. Lancet Oncol 21 : 335-337, 2020.
PubMed
33) Lippi G, Henry BM : Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19). Respir Med 167 : 105941, 2020.
PubMed
34) Myers LC, et al : Characteristics of Hospitalized Adults With COVID-19 in an Integrated Health Care System in California. JAMA 323 : 2195-2198, 2020.
 
35) Fadini GP, et al : Prevalence and impact of diabetes among people infected with SARS-CoV-2. J Endocrinol Invest 43 : 867-869, 2020.
PubMed
36) Zheng Z, et al : Risk factors of critical & mortal COVID-19 cases : A systematic literature review and meta-analysis. J Infect 81 : e16-e25, 2020.
 
37) Yang J, et al : Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2 : a systematic review and meta-analysis. Int J Infect Dis 94 : 91-95, 2020.
PubMed
38) Popkin BM, et al : Individuals with obesity and COVID-19 : A global perspective on the epidemiology and biological relationships. Obes Rev 21 : e13128, 2020.
PubMed
39) Latif F, et al : Characteristics and Outcomes of Recipients of Heart Transplant With Coronavirus Disease 2019. JAMA Cardiol 5 : 1165-1169, 2020.
PubMed
40) Mahdavinia M, et al : Asthma prolongs intubation in COVID-19. J Allergy Clin Immunol Pract 8 : 2388-2391, 2020.
PubMed
41) Brenner EJ, et al : Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases : Results From an International Registry. Gastroenterology 159 : 481-491.e3, 2020.
 
42) Michelena X, et al : Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs. Semin Arthritis Rheum 50 : 564-570, 2020.
 
43) Hadi YB, et al : Characteristics and outcomes of COVID-19 in patients with HIV : a multicentre research network study. AIDS 34 : F3-F8, 2020.
 
44) Ellington S, et al : Characteristics of Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status-United States, January 22-June 7, 2020. MMWR Morb Mortal Wkly Rep 69 : 769-775, 2020.
PubMed
45) Allotey J, et al : Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy : living systematic review and meta-analysis. BMJ 370 : m3320, 2020.
PubMed
46) COVID-19レジストリ研究運営事務局・運営委員会 : COVID-19レジストリデータを用いた新型コロナウイルス感染症における年齢別症例致命割合について. IASR 42 : 19-20, 2021.
 
47) Liang W, et al : Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19. JAMA Intern Med 180 : 1081-1089, 2020.
PubMed
48) Ji D, et al : Prediction for Progression Risk in Patients With COVID-19 Pneumonia : The CALL Score. Clin Infect Dis 71 : 1393-1399, 2020.
PubMed
49) Knight SR, et al : Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol : development and validation of the 4C Mortality Score. BMJ 370 : m3339, 2020.
PubMed
50) Yang Y, et al : Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19. J Allergy Clin Immunol 146 : 119-127.e4, 2020.
 
51) Silvin A, et al : Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19. Cell 182 : 1401-1418.e18, 2020.
 
52) Sugiyama M, et al : Serum CCL17 level becomes a predictive marker to distinguish between mild/moderate and severe/critical disease in patients with COVID-19. Gene 766 : 145145, 2021.
PubMed
53) Carfi A, et al : Persistent Symptoms in Patients After Acute COVID-19. JAMA 324 : 603-605, 2020.
PubMed
54) Garrigues E, et al : Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J Infect 81 : e4-e6, 2020.
PubMed
55) Miyazato Y, et al : Prolonged and late-onset symptoms of coronavirus disease 2019. Open Forum Infect Dis 7 : ofaa507, 2020.
PubMed
56) Shi H, et al : Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China : a descriptive study. Lancet Infect Dis 20 : 425-434, 2020.
 
57) Wang W, et al : Detection of SARS-CoV-2 in Different Typesof Clinical Specimens. JAMA 323 : 1843-1844, 2020.
 
58) Williams E, et al : Saliva as a Noninvasive Specimen for Detection of SARS-CoV-2. J Clin Microbiol 58 : e00776-20, 2020.
PubMed
59) Wyllie AL, et al : Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2. N Engl J Med 383 : 1283-1286, 2020.
 
60) World Health Organization : Laboratory biosafety guidance related to coronavirus disease 2019 (COVID-19) : interim guidance, 12 February 2020.
 
61) Ogawa T, et al : Another false-positive problem for a SARS-CoV-2 antigen test in Japan. J Clin Virol 131 : 104612, 2020.
PubMed
62) Gandhi RT, et al : Mild or Moderate Covid-19. N Engl J Med 383 : 1757-1766, 2020.
 
63) Wang M, et al : Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30 : 269-271, 2020.
PubMed
64) Wang Y, et al : Remdesivir in adults with severe COVID-19 : a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 395 : 1569-1578, 2020.
PubMed
65) Beigel JH, et al : Remdesivir for the Treatment of Covid-19-Final Report. N Engl J Med 383 : 1813-1826, 2020. (DOI : 10.1056/NEJMoa2007764)
 
66) Goldman JD, et al : Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med 383 : 1827-1837, 2020.
 
67) Spinner CD, et al : Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19 : A Randomized Clinical Trial. JAMA 324 : 1048-1057, 2020.
PubMed
68) Pan H, et al : Repurposed Antiviral Drugs for Covid-19-Interim WHO Solidarity Trial Results. N Engl J Med 384 : 497-511, 2021.
PubMed
69) Grein J, et al : Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med 382 : 2327-2336, 2020.
PubMed
70) Horby P, et al : Dexamethasone in Hospitalized Patients with Covid-19-Preliminary Report. N Engl J Med 384 : 693-704, 2021.
 
71) Kalil AC, et al : Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med 384 : 795-807, 2021.
PubMed
72) Adaptive COVID-19 Treatment Trial 4 (ACTT-4). [https://clinicaltrials.gov/ct2/show/NCT04640168]
 
73) Marconi VC, et al : Efficacy and safety of baricitinib in patients with COVID-19 infection : Results from the randomised, double-blind, placebo-controlled, parallel-group COV-BARRIER phase 3 trial. medRxiv, 2021. (DOI : 10.1101/2021.04.30.21255934)
 
74) Stone JH, et al : Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. N Engl Med 383 : 2333-2344, 2020.
PubMed
75) Salvarani C, et al : Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia : A Randomized Clinical Trial. JAMA Intern Med 181 : 24-31, 2021.
PubMed
76) Hermine O, et al : Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia : A Randomized Clinical Trial. JAMA Intern Med 181 : 32-40, 2021.
 
77) Salama C, et al : Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. N Engl J Med 384 : 20-30, 2021.
PubMed
78) REMAP-CAP Investigators, et al : Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med 384 : 1491-1502, 2021.
PubMed
79) RECOVERY Collaborative Group : Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial. Lancet 397 : 1637-1645, 2021.
 
80) Cao B, et al : A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med 382 : 1787-1799, 2020.
 
81) RECOVERY Collaborative Group, et al : Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med 383 : 2030-2040, 2020.
 
82) 小野薬品 : 蛋白分解酵素阻害剤「フオイパン錠」新型コロナウイルス感染症 (COVID-19) を対象とした国内第III相試験の結果について. 2021. 06. 11.
 
83) 国立国際医療研究センター : 吸入ステロイド薬シクレソニド (販売名 : オルベスコ) のCOVID-19を対象とした特定臨床研究結果速報について. 2020年12月23日.
 
P.147 掲載の参考文献
1) Mandell GL, et al : Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 7th ed, Churchill Livingstone, 2009.
 
2) Abbo LM, et al : Medical students' perceptions and knowledge about antimicrobial stewardship : how are we educating our future prescribers? Clin Infect Dis 57 : 631-638, 2013.
PubMed
3) 岸田直樹 : 誰も教えてくれなかった「風邪」の診かた : 感染症診療12の戦略 [第2版]. 医学書院, 2019.
 
4) 岸田直樹 : 総合診療医が教えるよくある気になるその症状レッドフラッグサインを見逃すな! じほう, 2015.
 
5) Petersen I, et al : Protective effect of antibiotics against serious complications of common respiratory tract infections : retrospective cohort study with the UK General Practice Research Database. BMJ 335 : 982, 2007.
PubMed
6) Shehab N, et al : Emergency department visits for antibiotic-associated adverse events. Clin Infect Dis 47 : 735-743, 2008.
PubMed
7) Turner RB : Epidemiology, pathogenesis, and treatment of the common cold. Ann Allergy Asthma Immunol 78 : 531-539 ; quiz 539-540, 1997.
 
8) 田坂佳千 : 'かぜ' 症候群の病型と鑑別疾患. 今日の治療 13 : 1217-1221, 2005.
 
P.155 掲載の参考文献
1) World Health Organization : Alert, verification and public health management of SARS in the post-outbreak period. 14 August 2003. [https://www.who.int/health-topics/severe-acute-respiratory-syndrome/technical-guidance/alert-verification-and-public-health-management-of-sars-in-the-post-outbreak-period]
 
2) Centers for Disease Control and Prevention (CDC) : Update : Outbreak of severe acute respiratory syndrome-worldwide, 2003. MMWR Morb Mortal Wkly Rep 52 : 241-246, 2003.
PubMed
3) Centers for Disease Control and Prevention (CDC) : Severe acute respiratory syndrome-Singapore, 2003. MMWR Morb Mortal Wkly Rep 52 : 405-411, 2003.
PubMed
4) Yu IT, et al : Evidence of airborne transmission of the severe acute respiratory syndrome virus. N Engl J Med 350 : 1731-1739, 2004.
PubMed
5) World Health Organization : Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. [http://www.who.int/csr/sars/country/table2004_04_21/en/index.html]
 
6) Peiris JS, et al : Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia : a prospective study. Lancet 361 : 1767-1772, 2003.
 
7) Lee N, et al : A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 348 : 1986-1994, 2003.
 
8) Hsu LY, et al : Severe acute respiratory syndrome (SARS) in Singapore : clinical features of index patient and initial contacts. Emerg Infect Dis 9 : 713-717, 2003.
PubMed
9) Booth CM, et al : Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA 289 : 2801-2809, 2003.
PubMed
10) Fraser C, et al : Factors that make an infectious disease outbreak controllable. Proc Natl Acad Sci USA 101 : 6146-6151, 2004.
PubMed
11) Leung GM, et al : Transmission dynamics and control of the viral etiological agent of SARS. In : Severe Acute Respiratory Syndrome (ed by Peiris M, et al), p111-130, Blackwell, Massachusetts, 2005.
 
12) Petrosillo N, et al : COVID-19, SARS and MERS : are they closely related? Clin Microbiol Infect 26 : 729-734, 2020.
PubMed
13) He X, et al : Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med 26 : 672-675, 2020.
PubMed
P.160 掲載の参考文献
1) Ong GM, et al : Herpes simplex type 1 shedding is associated with reduced hospital survival in patients receiving assisted ventilation in a tertiary referral intensive care unit. J Med Virol 72 : 121-125, 2004.
 
2) Feldman S : Varicella-zoster virus pneumonitis. Chest 106 : 22S-27S, 1994.
PubMed
3) Leung J, et al : Herpes zoster incidence among insured persons in the United States, 1993-2006 : evaluation of impact of varicella vaccination. Clin Infect Dis 52 : 332-340, 2011.
PubMed
4) Hall S, et al : Second varicella infections : are they more common than previously thought? Pediatrics 109 : 1068-1073, 2002.
PubMed
5) Ariyasu R, et al : Varicella Reinfection with Unilateral Varicella Pneumonia. Intern Med 55 : 3143-3145, 2016.
PubMed
6) Brodoefel H, et al : Herpes-Simplex-Virus 1 pneumonia in the immunocompromised host : high-resolution CT patterns in correlation to outcome and follow-up. Eur J Radiol 81 : e415-420, 2012.
PubMed
7) Chong S, et al : Herpes simplex virus pneumonia : high-resolution CT findings. Br J Radiol 83 : 585-589, 2010.
PubMed
8) Ramsey PG, et al : Herpes simplex virus pneumonia : clinical, virologic, and pathologic features in 20 patients. Ann Intern Med 97 : 813-820, 1982.
PubMed
9) Heimes E, et al : Effect of Antiviral Therapy on the Outcome of Mechanically Ventilated Patients With Herpes Simplex Virus Type 1 in BAL Fluid : A Retrospective Cohort Study. Chest 158 : 1867-1875, 2020.
PubMed
10) Traen S, et al : Is acyclovir effective among critically ill patients with herpes simplex in the respiratory tract? J Clin Virol 60 : 215-221, 2014.
PubMed
11) Schuierer L, et al : Impact of acyclovir use on survival of patients with ventilator-associated pneumonia and high load herpes simplex virus replication. Crit Care 24 : 12, 2020.
PubMed
12) Luyt CE, et al : Herpes simplex virus lung infection in patients undergoing prolonged mechanical ventilation. Am J Respir Crit Care Med 175 : 935-942, 2007.
PubMed
13) Morgan ER, Smalley LA : Varicella in immunocompromised children. Incidence of abdominal pain and organ involvement. Am J Dis Child 137 : 883-885, 1983.
PubMed
14) Feldman S, Lott L : Varicella in children with cancer : impact of antiviral therapy and prophylaxis. Pediatrics 80 : 465-472, 1987.
PubMed
P.164 掲載の参考文献
1) World Health Organization : Measles. [https://www.who.int/news-room/fact-sheets/detail/measles]
 
2) Roberts L : Why measles deaths are surging-and coronavirus could make it worse. Nature 580 : 446-447, 2020.
PubMed
3) Guha-Sapir D, et al : COVID-19 policies : Remember measles. Science 369 : 261, 2020.
PubMed
4) 国立感染症研究所感染症疫学センター : 麻疹とは. [https://www.niid.go.jp/niid/ja/diseases/ma/measles.html]
 
5) Hester G, et al : Measles Hospitalizations at a United States Children's Hospital 2011-2017. Pediatr Infect Dis J 38 : 547-552, 2019.
 
6) Centers for Disease Control and Prevention (CDC) : Chapter 13 : Measles. Epidemiology and Prevention of Vaccine-Preventable Disease. [https://www.cdc.gov/vaccines/pubs/pinkbook/meas.html]
 
7) Albarello F, et al : Pulmonary measles disease : old and new imaging tools. Radiol Med 123 : 935-943, 2018.
PubMed
8) Lombardo D, et al : Severe and fatal measles-associated pneumonia during an outbreak in Italy : data from the heart of the epidemic. Adv Respir Med 88 : 197-203, 2020.
PubMed
9) Ben-Chetrit E, et al : Measles-related hospitalizations and associated complications in Jerusalem, 2018-2019. Clin Microbiol Infect 26 : 637-642, 2020.
PubMed
10) Hai LT, et al : Adenovirus Type 7 Pneumonia in Children Who Died from Measles-Associated Pneumonia, Hanoi, Vietnam, 2014. Emerg Infect Dis 22 : 687-690, 2016.
 
11) Donadel M, et al : Risk factors for measles deaths among children during a Nationwide measles outbreak-Romania, 2016-2018. BMC Infect Dis 21 : 279, 2021.
PubMed
P.171 掲載の参考文献
1) Denning DW, et al : Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis. Bull World Health Organ 89 : 864-872, 2011.
PubMed
2) Page ID, et al : Chronic pulmonary aspergillosis commonly complicates treated pulmonary tuberculosis with residual cavitation. Eur Respir J 53 : 1801184, 2019.
PubMed
3) Kimura Y, et al : Prognostic factors of chronic pulmonary aspergillosis : A retrospective cohort of 264 patients from Japan. PLoS One 16 : e0249455, 2021.
PubMed
4) Tashiro T, et al : Diagnostic significance of Aspergillus species isolated from respiratory samples in an adult pneumology ward. Med Mycol 49 : 581-587, 2011.
 
5) アスペルギルス症の診断・治療ガイドライン 2015 (日本医真菌学会アスペルギルス症の診断・治療ガイドライン作成委員会編), 日本医真菌学会, 2015.
 
6) 深在性真菌症の診断・治療ガイドライン 2014 (深在性真菌症のガイドライン作成委員会編), 協和企画, 2014.
 
7) Denning DW, et al : Chronic pulmonary aspergillosis : rationale and clinical guidelines for diagnosis and management. Eur Respir J 47 : 45-68, 2016.
PubMed
8) Patterson TF, et al : Practice Guidelines for the Diagnosis and Management of Aspergillosis : 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 63 : e1-e60, 2016.
 
9) Takazono T, Izumikawa K : Recent Advances in Diagnosing Chronic Pulmonary Aspergillosis. Front Microbiol 9 : 1810, 2018.
PubMed
10) Pashley CH, et al : Routine processing procedures for isolating filamentous fungi from respiratory sputum samples may underestimate fungal prevalence. Med Mycol 50 : 433-438, 2012.
PubMed
11) Kohno S, et al : Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis : a multicenter trial in Japan. J Infect 61 : 410-418, 2010.
PubMed
12) Koyama K, et al : Recurrence of chronic pulmonary aspergillosis after discontinuation of maintenance treatment by antifungal triazoles. J Infect Chemother 20 : 375-379, 2014.
PubMed
13) 抗菌薬TDMガイドライン 2016 (抗菌薬TDMガイドライン作成委員会編), p39-41, 公益財団法人日本化学療法学会/一般社団法人日本TDM学会, 2016.
 
14) Chang SH, et al : Association Between Use of Non-Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation. JAMA 318 : 1250-1259, 2017.
PubMed
15) Nakamoto K, et al : Prognostic factors in 194 patients with chronic necrotizing pulmonary aspergillosis. Intern Med 52 : 727-734, 2013.
PubMed
P.175 掲載の参考文献
1) 山口英世 : アスペルギルス感染症. 病原真菌と真菌症, 改訂4版, p169-177, 南山堂, 2007.
 
2) アスペルギルス症の診断・治療ガイドライン 2015 (日本医真菌学会アスペルギルス症の診断・治療ガイドライン作成委員会編), 一般社団法人日本医真菌学会, 2015.
 
3) 深在性真菌症の診断・治療ガイドライン 2014 (深在性真菌症のガイドライン作成委員会編), 協和企画, 2014.
 
4) Suzuki Y, et al : Visceral Mycoses in Autopsied Cases in Japan from 1989 to 2013. Med Mycol J 59 : E53-E62, 2018.
PubMed
5) Mitaka H, et al : Incidence and mortality of COVID-19-associated pulmonary aspergillosis : A systematic review and meta-analysis. Mycoses 64 : 993-1001, 2021.
PubMed
6) Kula BE, et al : Invasive mould disease in fatal COVID-19 : a systematic review of autopsies. Lancet Microbe 2 : e405-e414, 2021.
PubMed
7) Donnelly JP, et al : Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis 71 : 1367-1376, 2020.
 
P.179 掲載の参考文献
1) Urabe N, et al : Molecular epidemiologic analysis of a Pneumocystis pneumonia outbreak among renal transplant patients. Clin Microbiol Infect 22 : 365-371, 2016.
PubMed
2) Nuesch R, et al : Pneumocystis carinii pneumonia in human immunodeficiency virus (HIV) -positive and HIV-negative immunocompromised patients. Clin Infect Dis 29 : 1519-1523, 1999.
PubMed
3) Liu Y, et al : Risk factors for mortality from pneumocystis carinii pneumonia (PCP) in non-HIV patients : a meta-analysis. Oncotarget 8 : 59729-59739, 2017.
PubMed
4) Deeks SG, et al : HIV infection. Nat Rev Dis Primers 1 : 15035, 2015.
 
5) Day CL, et al : PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443 : 350-354, 2006.
 
6) Wherry EJ : T cell exhaustion. Nat Immunol 12 : 492-499, 2011.
PubMed
7) Mecoli CA, et al : Pneumocystis jiroveci pneumonia in rheumatic disease : a 20-year single-centre experience. Clin Exp Rheumatol 35 : 671-673, 2017.
PubMed
8) Yale SH, Limper AH : Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome : associated illness and prior corticosteroid therapy. Mayo Clin Proc 71 : 5-13, 1996.
PubMed
9) Ghembaza A, et al : Risk Factors and Prevention of Pneumocystis jirovecii Pneumonia in Patients With Autoimmune and Inflammatory Diseases. Chest 158 : 2323-2332, 2020.
PubMed
10) Atsumi T, et al : The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, COPERA, shows inhibition of radiographic progression. Ann Rheum Dis 75 : 75-83, 2016.
 
11) McKinnell JA, et al : Pneumocystis pneumonia in hospitalized patients : a detailed examination of symptoms, management, and outcomes in human immunodeficiency virus (HIV) -infected and HIV-uninfected persons. Transpl Infect Dis 14 : 510-518, 2012.
PubMed
12) Tasaka S, et al : Serum indicators for the diagnosis of pneumocystis pneumonia. Chest 131 : 1173-1180, 2007.
 
13) Tasaka S, et al : Comparison of clinical and radiological features of pneumocystis pneumonia between malignancy cases and acquired immunodeficiency syndrome cases : a multicenter study. Intern Med 49 : 273-281, 2010.
 
14) Utsunomiya M, et al : Optimal regimens of sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with systemic rheumatic diseases : results from a non-blinded, randomized controlled trial. Arthritis Res Ther 19 : 7, 2017.
 
15) Pareja JG, et al : Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. Chest 113 : 1215-1224, 1998.
PubMed
P.181 掲載の参考文献
1) Wisplinghoff H, et al : Nosocomial bloodstream infections in US hospitals : analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39 : 309-317, 2004.
PubMed
2) Shimodaira K, et al : Trends in the prevalence of invasive fungal infections from an analysis of annual records of autopsy cases of Toho University. Mycoses 55 : 435-443, 2012.
PubMed
3) Okuno D, et al : Duration of antifungal therapy for septic pulmonary embolism caused by Candida albicans from a central venous catheter : A case report. Clin Case Rep 9 : 707-710, 2021.
PubMed
4) 日本医真菌学会侵襲性カンジダ症の診断・治療ガイドライン 2013 (日本医真菌学会侵襲性カンジダ症の診断・治療ガイドライン作成委員会編), 日本医真菌学会, 2013.
 
P.186 掲載の参考文献
1) Woodring JH, et al : Pulmonary cryptococcosis. Semin Roentgenol 31 : 67-75, 1996.
PubMed
2) Setianingrum F, et al : Pulmonary cryptococcosis : A review of pathobiology and clinical aspects. Med Mycol 57 : 133-150, 2019.
PubMed
3) Park BJ, et al : Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23 : 525-530, 2009.
PubMed
4) Kohno S, et al : Clinical features of pulmonary cryptococcosis in non-HIV patients in Japan. J Infect Chemother 21 : 23-30, 2015.
PubMed
5) Okamoto K, et al : Cryptococcus gattii genotype VGIIa infection in man, Japan, 2007. Emerg Infect Dis 16 : 1155-1157, 2010.
PubMed
6) Acheson ES, et al : Searching for clues for eighteen years : Deciphering the ecological determinants of Cryptococcus gattii on Vancouver Island, British Columbia. Med Mycol 56 : 129-144, 2018.
PubMed
7) Garcia-Rivera J, et al : Cryptococcus neoformans CAP59 (or Cap59p) is involved in the extracellular trafficking of capsular glucuronoxylomannan. Eukaryot Cell 3 : 385-392, 2004.
PubMed
8) Pukkila-Worley R, et al : Transcriptional network of multiple capsule and melanin genes governed by the Cryptococcus neoformans cyclic AMP cascade. Eukaryot Cell 4 : 190-201, 2005.
PubMed
9) Singh A, et al : Factors required for activation of urease as a virulence determinant in Cryptococcus neoformans, mBio 4 : e00220-213, 2013.
PubMed
10) Tanner DC, et al : Comparison of commercial kits for detection of cryptococcal antigen. J Clin Microbiol 32 : 1680-1684, 1994.
PubMed
11) Senghor Y, et al : Cryptococcal antigen detection in broncho-alveolar lavage fluid. Med Mycol 56 : 774-777, 2018.
PubMed
12) 道津安正, ほか : 肺クリプトコッカス症16例の臨床的検討-血清クリプトコッカス抗原価の推移に着目して-. 感染症学雑誌 79 : 656-663, 2005.
 
13) de Andrade IB, et al : Production of Secreted Carbohydrates that Present Immunologic Similarities with the Cryptococcus Glucuronoxylomannan by Members of the Trichosporonaceae Family : A Comparative Study Among Species of Clinical Interest. Mycopathologia 186 : 377-385, 2021.
 
14) Miyazaki T, et al : Plasma (1→3) -β-D-glucan and fungal antigenemia in patients with candidemia, aspergillosis, and cryptococcosis. J Clin Microbiol 33 : 3115-3118, 1995.
 
15) Pappas PG, et al : Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis 33 : 690-699, 2001.
PubMed
P.190 掲載の参考文献
1) Shimazu K, et al : Hypersensitivity pneumonitis induced by Trichosporon cutaneum. Am Rev Respir Dis 130 : 407-411, 1984.
PubMed
2) 第3章 深在性真菌症の診断と治療のフローチャート解説. 深在性真菌症の診断・治療ガイドライン 2014 (深在性真菌症のガイドライン作成委員会編), p115-155, 協和企画, 2014.
 
3) Liu XZ, et al : Towards an integrated phylogenetic classification of the Tremellomycetes. Stud Mycol 81 : 85-147, 2015.
PubMed
4) Suzuki Y, et al : Visceral Mycoses in Autopsied Cases in Japan from 1989 to 2013. Med Mycol J 59 : E53-E62, 2018.
PubMed
5) Sadamoto S, et al : Histopathological study on the prevalence of trichosporonosis in formalin-fixed and paraffin-embedded tissue autopsy sections by in situ hybridization with peptide nucleic acid probe. Med Mycol 58 : 460-468, 2020.
 
6) Kim J, et al : Comparison of the characteristics of patients with invasive infections and noninvasive infections caused by Trichosporon asahii. Med Mycol 59 : 296-300, 2021.
PubMed
7) Kuo SH, et al : The epidemiology, genotypes, antifungal susceptibility of Trichosporon species, and the impact of voriconazole on Trichosporon fungemia patients. J Formos Med Assoc 120 : 1686-1694, 2021.
PubMed
8) Meyer MH, et al : Chronic disseminated Trichosporon asahii infection in a leukemic child. Clin Infect Dis 35 : e22-25, 2002.
 
9) Segrelles-Calvo G, et al : Trichosporon asahii as Cause of Nosocomial Pneumonia in Patient With COVID-19 : A Triple Co-infection. Arch Bronconeumol 57 (Suppl 2) : 46-48, 2021.
 
10) Marklein G, et al : Matrix-assisted laser desorption ionization-time of flight mass spectrometry for fast and reliable identification of clinical yeast isolates. J Clin Microbiol 47 : 2912-2917, 2009.
PubMed
11) McManus EJ, Jones JM : Detection of a Trichosporon beigelii antigen cross-reactive with Cryptococcus neoformans capsular polysaccharide in serum from a patient with disseminated Trichosporon infection. J Clin Microbiol 21 : 681-685, 1985.
PubMed
12) Girmenia C, et al : Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies : a retrospective multicenter study from Italy and review of the literature. J Clin Microbiol 43 : 1818-1828, 2005.
PubMed
13) Ruan SY, et al : Invasive trichosporonosis caused by Trichosporon asahii and other unusual Trichosporon species at a medical center in Taiwan. Clin Infect Dis 49 : e11-17, 2009.
 
14) Francisco EC, et al : Correlation of Trichosporon asahii Genotypes with Anatomical Sites and Antifungal Susceptibility Profiles : Data Analyses from 284 Isolates Collected in the Last 22 Years across 24 Medical Centers. Antimicrob Agents Chemother 65 : e01104-e01120, 2021.
PubMed
15) Itoh K, et al : Successful Treatment of Breakthrough Trichosporon asahii Fungemia by the Combination Therapy of Fluconazole and Liposomal Amphotericin B in a Patient with Follicular Lymphoma. Mycopathologia 186 : 113-117, 2021.
 
P.194 掲載の参考文献
1) Prakash H, Chakrabarti A : Global Epidemiology of Mucormycosis. J Fungi (Basel) 5 : 26, 2019.
 
2) Baldin C, Ibrahim AS : Molecular mechanisms of mucormycosis-The bitter and the sweet. PLoS Pathog 13 : e1006408, 2017.
PubMed
3) 深在性真菌症のガイドライン作成委員会 (編) : 深在性真菌症の診断・治療ガイドライン 2014. 第2章 深在真菌症の疫学, 診断法および治療戦略. 3病理組織学的診断, p72-87, 協和企画, 2014.
 
4) Suzuki Y, et al : Epidemiology of Zygomycosis : Analysis of National Data from Pathological Autopsy Cases in Japan. Med Mycol J 58 : E89-E95, 2017.
PubMed
5) 深在性真菌症のガイドライン作成委員会 (編) : 深在性真菌症の診断・治療ガイドライン 2014. 第3章 深在性真菌症の診断と治療のフローチャート解説. A 血液疾患領域. p116-142, 協和企画, 2014.
 
6) Garg D, et al : Coronavirus Disease (Covid-19) Associated Mucormycosis (CAM) : Case Report and Systematic Review of Literature. Mycopathologia 186 : 289-298, 2021.
PubMed
7) Cornely OA, et al ; Mucormycosis ECMM MSG Global Guideline Writing Group : Global guideline for the diagnosis and management of mucormycosis : an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis 12 : e405-e421, 2019.
 
8) Kontoyiannis DP, Lewis R : Agents of Mucormycosis and Entomophthoramycosis. In : Mandell, Dougas, and Benett's Principles and Practice of Infectious Disease, 9th ed (ed by Benett JE, et al), p3117-3130, Elsevier, Philadelphia, 2020.
 
9) 木村雅友 : 糸状菌感染症を中心とした病理診断と病態. 深在性真菌症 病理診断アップデートレビュー (安藤常浩, ほか編), p55-63, 協和企画, 2012.
 
10) Spellberg B, et al : Novel perspectives on mucormycosis : pathophysiology, presentation, and management. Clin Microbiol Rev 18 : 556-569, 2005.
PubMed
11) Agrawal R, et al : Pulmonary Mucormycosis : Risk Factors, Radiologic Findings, and Pathologic Correlation. Radiographics 40 : 656-666, 2020.
PubMed
12) Chamilos G, et al : Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis 41 : 60-66, 2005.
PubMed
13) Shibata W, et al : Detection of Rhizopus-specific antigen in human and murine serum and bronchoalveolar lavage. Med Mycol 58 : 958-964, 2020.
PubMed
14) Roden MM, et al : Epidemiology and outcome of zygomycosis : a review of 929 reported cases. Clin Infect Dis 41 : 634-653, 2005.
PubMed
15) Lin E, et al : Pulmonary mucormycosis : clinical features and outcomes. Infection 45 : 443-448, 2017.
PubMed
P.199 掲載の参考文献
1) Sponseller JK, et al : The evolution of respiratory Cryptosporidiosis : evidence for transmission by inhalation. Clin Microbiol Rev 27 : 575-586, 2014.
PubMed
2) Feng Y, et al : Genetic Diversity and Population Structure of Cryptosporidium. Trends Parasitol 34 : 997-1011, 2018.
PubMed
3) 鈴木淳, ほか : 都内で発生したクリプトスポリジウムによる集団感染事例. 日本臨床寄生虫学会誌 26 : 9-12, 2015.
 
4) Guerrant RL : Cryptosporidiosis : an emerging, highly infectious threat. Emerg Infect Dis 3 : 51-57, 1997.
PubMed
5) McCarty M, et al : Radiological features of AIDS related cholangitis. Clin Radiol 40 : 582-585, 1989.
PubMed
6) Dolmatch BL, et al : AIDS-related cholangitis : radiographic findings in nine patients. Radiology 163 : 313-316, 1987.
PubMed
7) Denkinger CM, et al : Cryptosporidium parvum-associated sclerosing cholangitis in a liver transplant patient. Transpl Infect Dis 10 : 133-136, 2008.
 
8) Rodrigues F, et al : Liver disease in children with primary immunodeficiencies. J Pediatr 145 : 333-339, 2004.
PubMed
9) Levy J, et al : Clinical spectrum of X-linked hyper-IgM syndrome. J Pediatr 131 : 47-54, 1997.
PubMed
10) Clavel A, et al : Respiratory cryptosporidiosis : case series and review of the literature. Infection 24 : 341-346, 1996.
PubMed
11) Mor SM, et al : Respiratory cryptosporidiosis in HIV-seronegative children in Uganda : potential for respiratory transmission. Clin Infect Dis 50 : 1366-1372, 2010.
PubMed
12) Buret AG, et al : Infection of human and bovine epithelial cells with Cryptosporidium andersoni induces apoptosis and disrupts tight junctional ZO-1 : effects of epidermal growth factor. Int J Parasitol 33 : 1363-1371, 2003.
PubMed
13) Dolmatch BL, et al : AIDS-related cholangitis : radiographic findings in nine patients. Radiology 163 : 313-316, 1987.
PubMed
14) Martinez F, et al : In vitro multiplication of Cryptosporidium parvum in mouse peritoneal macrophages. Vet Parasitol 42 : 27-31, 1992.
PubMed
15) Hojlyng N, et al : Cryptosporidiosis : a case of airborne transmission. Lancet 2 : 271-272, 1987.
PubMed
16) 所正治, ほか : 免疫低下にともなうMAC感染症に合併した呼吸器クリプトスポリジウム症の一例. 日本臨床寄生虫学会誌 19 : 55-58, 2008.
 
P.203 掲載の参考文献
1) 吉田幸雄 : 図説人体寄生虫学 [改訂10版] (日本寄生虫学会図説人体寄生虫学編集委員会編), 2021.
 
2) Hung CC, et al : Entamoeba histolytica infection in men who have sex with men. Lancet Infect Dis 12 : 729-736, 2012.
PubMed
3) Escoa-Verge L, et al : Outbreak of intestinal amoebiasis among men who have sex with men, Barcelona (Spain), October 2016 and January 2017. Eur Surveill 22 : 30581, 2017.
 
4) 国立感染症研究所 : 感染症発生動向調査. [https://www.niid.go.jp/niid]
 
5) Blessmann J, et al : Longitudinal study of intestinal Entamoeba histolytica infections in asymptomatic adult carriers. J Clin Microbiol 41 : 4745-4750, 2003.
PubMed
6) Watanabe K, et al : Asymptomatic intestinal amebiasis in Japanese HIV-1-infected individuals. Am J Trop Med Hyg 91 : 816-820, 2014.
PubMed
7) Shirley DA, et al : Fulminant Amebic Colitis after Corticosteroid Therapy : A Systematic Review. PLoS Negl Trop Dis 10 : e0004879, 2016.
PubMed
8) Adams EB, et al : Invasive amebiasis. I. Amebic dysentery and its complications. Medicine (Baltimore) 56 : 315-323, 1977.
PubMed
9) Otan E, et al : Amebic acute appendicitis : systematic review of 174 cases. World J Surg 37 : 2061-2073, 2013.
PubMed
10) Kobayashi T, et al : Underestimated Amoebic Appendicitis among HIV-1-Infected Individuals in Japan. J Clin Microbiol 55 : 313-320, 2017.
PubMed
11) 古賀道子 : 赤痢アメーバ症. 寄生虫症薬物治療の手引き-2020- [改訂第10.2版] (熱帯病治療薬研究班), p8-12, 2020.
 
12) Irusen EM, et al : Asymptomatic intestinal colonization by pathogenic Entamoeba histolytica in amebic liver abscess : prevalence, response to therapy, and pathogenic potential. Clin Infect Dis 14 : 888-893, 1992.
 
13) Watanabe K, et al : Amebiasis in HIV-1-infected Japanese men : clinical features and response to therapy. PLoS Negl Trop Dis 5 : e1318, 2011.
PubMed
P.209 掲載の参考文献
1) Horio M, et al : Risk of Toxoplasma gondii infection in slaughterhouse workers in Kitakyushu City. J UOEH 23 : 233-243, 2001.
 
2) Smith AB, et al : From the archives of the AFIP : central nervous system infections associated with human immunodeficiency virus infection : radiologic-pathologic correlation. Radiographics 28 : 2033-2058, 2008. Erratum in : Radiographics 29 : 638, 2009.
 
3) Hogan MJ, et al : Ocular toxoplasmosis. Arch Ophthalmol 72 : 592-600, 1964.
PubMed
4) Remington JS, McLeod R : Toxoplasmosis. In : Medical Microbiology and Infectious Diseases, (ed by Braude AI), p1816-1832, W. B. Saunders Co., Philadelphia, 1981.
 
5) Mikita K, et al : The utility of cerebrospinal fluid for the molecular diagnosis of toxoplasmic encephalitis. Diagn Microbiol Infect Dis 75 : 155-159, 2013.
PubMed
6) Roche AD, et al : Concentric and Eccentric Target MRI Signs in a Case of HIV-Associated Cerebral Toxoplasmosis. Case Rep Neurol Med 2018 : 9876514, 2018.
 
7) Sakai M, et al : MRI imaging features of HIV-related central nervous system diseases : diagnosis by pattern recognition in daily practice. Jpn J Radiol, 2021. (DOI : 10.1007/s11604-021-01150-4)
 
8) Marcus C, et al : Imaging in Differentiating Cerebral Toxoplasmosis and Primary CNS Lymphoma With Special Focus on FDG PET/CT. AJR Am J Roentgenol 216 : 157-164, 2021.
PubMed
9) Schroeder PC, et al : Analysis of the utility of diffusion-weighted MRI and apparent diffusion coefficient values in distinguishing central nervous system toxoplasmosis from lymphoma. Neuroradiology 48 : 715-720, 2006.
PubMed
10) 堀内一宏, ほか : 特異的画像所見を示しIgG avidity indexとnested PCRにて診断したトキソプラズマ脳症の一例. 臨床神経 50 : 252-256, 2010.
 
11) Sumi M, et al : Clinical characteristics and computed tomography findings of pulmonary toxoplasmosis after hematopoietic stem cell transplantation. Int J Hematol 104 : 729-740, 2016.
PubMed
12) Escuissato DL, et al : Disseminated toxoplasmosis after bone marrow transplantation : high-resolution CT appearance. J Thorac Imaging 19 : 207-209, 2004.
 
13) Schmidt M, et al : Clinical features and outcomes in patients with disseminated toxoplasmosis admitted to intensive care : a multicenter study. Clin Infect Dis 57 : 1535-1541, 2013.
PubMed
14) Miyata N, et al : Desensitization to trimethoprim-sulfamethoxazole in a toxoplasmic encephalitis patient who was intolerant to conventional treatments. J Infect Chemother 26 : 289-293, 2020.
 
15) Pomeroy C, Filice GA : Pulmonary toxoplasmosis : a review. Clin Infect Dis 14 : 863-870, 1992.
PubMed
P.214 掲載の参考文献
1) Jelinek T, et al : Malaria in nonimmune travelers : A synopsis of history, symptoms, and treatment in 160 patients. J Travel Med 1 : 199-202, 1994.
PubMed
2) Taylor WR, et al : Pulmonary manifestations of malaria : recognition and management. Treat Respir Med 5 : 419-428, 2006.
PubMed
3) Takaya S, et al : Case Report : Plasmodium knowlesi infection with rhabdomyolysis in a Japanese traveler to Palawan, the Philippines. Am J Trop Med Hyg 99 : 967-969, 2018.
 
4) WHO Global Malaria Program : Global trends in the burden of malaria. In : World Malaria Report 2020 (ed by WHO), p18-37, WHO Press, Geneva, 2020.
 
5) Menard D, et al : A worldwide map of Plasmodium falciparum K13-propeller polymorphisms. N Engl J Med 374 : 2453-2464, 2016.
 
6) WHO : Severe falciparum malaria. Trans R Soc Trop Med Hyg 94 (suppl) : S1-S90, 2000.
 
7) Kawai S, et al : A primate model for severe human malaria with cerebral involvement : Plasmodium coatneyi-infected Macaca fuscata. Am J Trop Med Hyg 48 : 630-636, 1993.
PubMed
8) Deaton JG : Fatal pulmonary edema as a complication of acute falciparum malaria. Am J Trop Med Hyg 19 : 196-201, 1970.
 
9) Krudsood S, et al : Malaria in Thailand. In : Asian Parasitology 6 : Malaria in Asia (ed by Kano S, Rivera PT), p1-84, FAP Journal Ltd, Chiba, 2005.
 
10) Illamperuma C, Allen BL : Pulmonary edema due to Plasmodium vivax malaria in an American missionary. Infection 35 : 374-376, 2007.
 
11) Duarte MI, et al : Ultrastructure of the lung in falciparum malaria. Am J Trop Med Hyg 34 : 31-35, 1985.
PubMed
12) Aursudkij B, et al : Pulmonary edema in cerebral malaria patients in Thailand. Southeast Asian J Trop Med Public Health 29 : 541-545, 1998.
PubMed
13) 駒木-安田加奈子, ほか : PURE/LAMP法のマラリア診断への応用. Clin Parasitol 26 : 83-85, 2015.
 
14) Wilairatana P, Looareesuwan S : Guideline in management of severe malaria. J Indian Med Assoc 98 : 628-631, 2000.
PubMed
15) 海老沢功, ほか : 熱帯熱マラリア治療における開始遅延の意義. 日本熱帯医学会雑誌 19 : 49-56, 1991.
 
P.220 掲載の参考文献
1) World Health Organization : Leishmaniasis. [https://www.who.int/health-topics/leishmaniasis]
 
2) Sereno D : Leishmania (Mundinia) spp. : from description to emergence as new human and animal Leishmania pathogens. New Microbes New Infect 30 : 100540, 2019.
PubMed
3) Bispo AJB, et al : Pulmonary involvement in human visceral leishmaniasis : Clinical and tomographic evaluation. PLoS One 15 : e0228176, 2020.
PubMed
4) Kato H, et al : Prevalence of Genetically Complex Leishmania Strains With Hybrid and Mito-Nuclear Discordance. Front Cell Infect Microbiol 11 : 625001, 2021.
PubMed
5) Roatt BM, et al : Recent advances and new strategies on leishmaniasis treatment. Appl Microbiol Biotechnol 104 : 8965-8977, 2020.
PubMed
P.224 掲載の参考文献
1) 吉田幸雄, 有薗直樹 : 幼虫移行症. 図説人体寄生虫学 改訂10版, p98-99, 南山堂, 2021.
 
2) Ma G, et al : Human toxocariasis. Lancet Infect Dis 18 : e14-e24, 2018.
PubMed
3) Akao N, Ohta N : Toxocariasis in Japan. Parasitol Int 56 : 87-93, 2007.
PubMed
4) 山本徳栄 : 食品媒介によるトキソカラ症. 日本食品微生物学会雑誌 31 : 1-12, 2014.
Medical*Online
5) Yoshikawa M, et al : A familial case of visceral toxocariasis due to consumption of raw bovine liver. Parasitol Int 57 : 525-529, 2008.
PubMed
6) 吉田彩子, ほか : 海外渡航時の生肉摂取により感染したと考えられる回虫類幼虫移行症. Clinical Parasitology 25 : 34-37, 2014.
 
7) Hur JH, et al : Chest CT findings of toxocariasis : correlation with laboratory results. Clin Radiol 69 : e285-290, 2014.
PubMed
8) Park BM, et al : Differences in the clinical and radiological characteristics of lung-involved toxocariasis between toxocariasis with eosinophilia and those without eosinophilia. J Thorac Dis 6 : 1757-1764, 2014.
PubMed
9) Sakai S, et al : Pulmonary lesions associated with visceral larva migrans due to Ascaris suum or Toxocara canis : imaging of six cases. AJR Am J Roentgenol 186 : 1697-1702, 2006.
PubMed
10) 吉川正英, ほか : 成人肺トキソカラ症8例の臨床的検討. 日本呼吸器学会誌 48 : 351-356, 2010.
 
11) 大城康二, ほか : 肺寄生虫疾患. 画像診断 36 : 309-317, 2016.
Medical*Online
12) Noordin R, et al : Serodiagnostic methods for diagnosing larval toxocariasis. Adv Parasitol 109 : 131-152, 2020.
PubMed
13) Magnaval JF, Glickman LT : Management and treatment options for human toxocariasis. In : Toxocara : The Enigmatic Parasite (ed by Holland CV, Smith HV), p113-126, CABI Publishing, Cambridge, 2006.
 
P.229 掲載の参考文献
1) 吉田幸雄 : イヌ糸状虫. 図説人体寄生虫学, 改訂10版, p140-141, 南山堂, 2021.
 
2) Akao N : Human dirofilariasis in Japan. Trop Med Health 39 : 65-71, 2011.
PubMed
3) CDC ; Centers for Disease Control and Prevention : Dirofilariasis FAQs. [https://www.cdc.gov/parasites/dirofilariasis/faqs.html]
 
4) Asimacopoulos PJ, et al : Pulmonary dirofilariasis. The largest single-hospital experience. Chest 102 : 851-855, 1992.
PubMed
5) 真喜屋清, ほか : 日本における犬糸状虫の人体寄生症例総覧. 産業医科大学雑誌 9 : 233-242, 1987.
 
6) Fortin JF, Slocombe JOD : Temperature requirements for the development of Dirofilaria immitis in Aedes triseriatus and Ae. vexans. Mosquito News 41 : 625-633, 1981.
 
7) Knight DH, Lok JB : Seasonality of heartworm infection and implications for chemoprophylaxis. Clin Tech Small Anim Pract 13 : 77-82, 1998.
PubMed
8) Atsumi E, et al : Thirteen cases of pulmonary dirofilariasis in a single institution in Okinawa Island. Virchows Arch 475 : 335-340, 2019.
 
9) Flieder DB, Moran CA : Pulmonary dirofilariasis : a clinicopathologic study of 41 lesions in 39 patients. Hum Pathol 30 : 251-256, 1999.
PubMed
10) Milanez de Campos JR, et al : Human pulmonary dirofilariasis : analysis of 24 cases from Sao Paulo, Brazil. Chest 112 : 729-733, 1997.
 
11) 山上由理子, ほか :. 大量の血性胸水貯留をきたした肺犬糸状虫症の1例. 日本呼吸器学会雑誌 36 : 560-563, 1998.
Medical*Online
12) 小笠原隆, ほか : 犬糸状虫による好酸球性胸水の1例. 日本呼吸器学会雑誌 41 : 347-350, 2003.
Medical*Online
13) 堤寛 : フィラリア症, オンコセルカ症, イヌ糸状虫症. 感染症病理アトラス, p244-246, 文光堂, 2000.
 
14) Araya J, et al : Allergic inflammatory reaction is involved in necrosis of human pulmonary dirofilariasis. Histopathology 51 : 484-490, 2007.
PubMed
15) Mukhopadhyay S : Dirofilariasis. In : Non-Neoplastic Pulmonary Pathology ; An Algorithmic Approach to Histologic Findings in the Lung, p82-83, Cambridge University Press, Cambridge, 2016.
 
P.234 掲載の参考文献
1) Kikuchi T, et al : Genome of the fatal tapeworm Sparganum proliferum uncovers mechanisms for cryptic life cycle and aberrant larval proliferation. Commun Biol 4 : 649, 2021.
PubMed
2) Kikuchi T, Maruyama H : Human proliferative sparganosis update. Parasitol Int 75 : 102036, 2020.
PubMed
3) Alarcon de Noya B, et al : Maintenance of Sparganum proliferum in vitro and in experimental animals. Int J Parasitol 22 : 835-838, 1992.
PubMed
4) Miyadera H, et al : Phylogenetic identification of Sparganum proliferum as a pseudophyllidean cestode by the sequence analyses on mitochondrial COI and nuclear sdhB genes. Parasitol Int 50 : 93-104, 2001.
PubMed
5) Kuchta R, et al : Sparganosis (Spirometra) in Europe in the Molecular Era. Clin Infect Dis 72 : 882-890, 2021.
PubMed
6) Arrabal JP, et al : First identification and molecular phylogeny of Sparganum proliferum from endangered felid (Panthera onca) and other wild definitive hosts in one of the regions with highest worldwide biodiversity. Int J Parasitol Parasites Wildl 13 : 142-149, 2020.
PubMed
7) 山崎浩, ほか : 連節条虫によるヒト脳共尾虫症の第1例. 日本臨床寄生虫学会誌 30 : 52-54, 2019.
 
8) Lehman B, et al : Disseminated Metacestode Versteria Species Infection in Woman, Pennsylvania, USA. Emerg Infect Dis 25 : 1429-1431, 2019.
PubMed
9) Barkati S, et al : First Human Case of Metacestode Infection Caused by Versteria sp. in a Kidney Transplant Recipient. Clin Infect Dis 68 : 680-683, 2019.
 
P.238 掲載の参考文献
1) 杉山広 : 肺吸虫 (食品による寄生動物感染症 (7) 蠕虫感染症 (2)). 日本防菌防黴学会誌 41 : 165-171, 2013.
 
2) 栗山満美子, ほか : 胸水出現から診断に2年を要したウェステルマン肺吸虫症の1例. 日本呼吸器学会誌 8 : 391-395, 2019.
 
3) Nakagawa Y, et al : An outbreak of Paragonimus westermani infection among Cambodian technical intern trainees in Japan, exhibiting various extrapulmonary lesions. Parasitol Int 81 : 102279, 2021.
PubMed
4) Sugiyama H, et al : Paragonimiasis due to the consumption of wild boar meat in Japan : contamination levels of lung fluke larvae in muscle samples of wild boars caught in Kagoshima Prefecture. Jpn J Infect Dis 68 : 536-537, 2015.
 
5) Yoshida A, et al : Venison, another source of Paragonimus westermani infection. Parasitol Int 65 : 607-612, 2016.
PubMed
6) Sugiyama H, et al : Paragonimus (Chapter 39). In : Molecular Detection of Human Parasitic Pathogens (ed by Liu D), p423-435, CRC Press, Boca Raton, 2013.
 
7) 吉松裕介, ほか : 在日ミャンマー人のヒロクチ肺吸虫症の1例. Clin Parasitol 24 : 106-108, 2013.
 
8) 長島則夫, ほか : Klebsiella感染をきっかけとして発見された宮崎とウェステルマン肺吸虫症の中間型と考えられる肺吸虫症の1例. 内科 43 : 323-327, 1979.
 
9) Nagayasu E, et al : Paragonimiasis in Japan : a twelve-year retrospective case review (2001-2012). Intern Med 54 : 179-186, 2015.
PubMed
10) 飯島淳司, ほか : 診断に苦慮した胸水の経過観察中にウェステルマン肺吸虫症と診断した1例. 呼吸器内科 37 : 213-218, 2020.
 
11) 丸山治彦 : 肺吸虫症. 寄生虫症薬物治療の手引き-2020-改訂第10.2版 (丸山治彦, ほか編), p49-50, 日本医療研究開発機構 新興・再興感染症に対する革新的医薬品等開発推進研究事業「わが国における熱帯病・寄生虫症の最適な診断治療予防体制の構築」 (略称 : 熱帯病治療薬研究班), 2020. [https://www.nettai.org]
 
12) 岡本秀雄, ほか : 喀痰細胞診にて虫卵を認めた肺吸虫症の2例. 日本臨床細胞学会誌 53 : 292-297, 2014.
 
13) Irie T, et al : Evaluation of the MGL method to detect Paragonimus eggs and its improvement. Parasitol Res 114 : 4051-4058, 2015.
PubMed
14) 松本俊郎, ほか : ウェステルマン肺吸虫症のCT所見. 日本医学放射線学会雑誌 53 : 565-571, 1993.
 
P.243 掲載の参考文献
1) Buonfrate D, et al : The Global prevalence of Strongyloides stercoralis infection. Pathogens 9 : 468, 2020.
 
2) Tanaka T, et al : Relationship Among Strongyloides stercoralis Infection, Human T-Cell Lymphotropic Virus Type 1 Infection, and Cancer : A 24-Year Cohort Inpatient Study in Okinawa, Japan. Am J Trop Med Hyg 94 : 365-370, 2016.
 
3) Hirata T, et al : Impairment of host immune response against Strongyloides stercoralis by human T cell lymphotropic virus type 1 infection. Am J Trop Med Hyg 74 : 246-249, 2006.
PubMed
4) Montes M, et al : Regulatory T cell expansion in HTLV-1 and strongyloidiasis co-infection is associated with reduced IL-5 responses to Strongyloides stercoralis antigen. PLoS Negl Trop Dis 3 : e456, 2009.
PubMed
5) Saito A : Strongyloidiasis : Epidemiology, clinical manifestations and new methods for diagnosis and treatment. J Infect Chemother 1 : 98-106, 1995.
 
6) Fardet L, et al : Severe strongyloidiasis in corticosteroid-treated patients : case series and literature review. J Infect 54 : 18-27, 2007.
PubMed
7) Zaha O, et al : Strongyloidiasis-progress in diagnosis and treatment. Intern Med 39 : 695-700, 2000.
PubMed
8) Arakaki T, et al : Efficacy of agar-plate culture in detection of Strongyloides stercoralis infection. J Parasitol 76 : 425-428, 1990.
PubMed
9) Smith B, et al : Pulmonary strongyloidiasis. Diagnosis by sputum gram stain. Am J Med 79 : 663-666, 1985.
 
10) Namisato S, et al : Pulmonary strongyloidiasis in a patient receiving prednisolone therapy. Intern Med 43 : 731-736, 2004.
 
11) Chu E, et al : Pulmonary hyperinfection syndrome with Strongyloides stercoralis. Chest 97 : 1475-1477, 1990.
PubMed
12) Kinjo T, et al : Acute respiratory distress syndrome due to Strongyloides stercoralis infection in a patient with cervical cancer. Intern Med 54 : 83-87, 2015.
 
13) Nabeya D, et al : Pulmonary strongyloidiasis : assessment between manifestation and radiological findings in 16 severe strongyloidiasis cases. BMC Infect Dis 17 : 320, 2017.
PubMed
14) 金城福則, ほか : 寄生虫性感染症 糞線虫症. 胃と腸 37 : 437-441, 2002.
 
15) Zaha O, et al : Comparison of anthelmintic effects of two doses of ivermectin on intestinal strongyloidiasis in patients negative or positive for anti-HTLV-1 antibody. J Infect Chemother 10 : 348-351, 2004.
PubMed
P.247 掲載の参考文献
1) Venkat B, et al : A comprehensive review of imaging findings in human cysticercosis. Jpn J Radiol 34 : 241-257, 2016.
PubMed
2) Schantz PM, et al : Neurocysticercosis in an Orthodox Jewish community in New York City. N Engl J Med 327 : 692-695, 1992.
 
3) Ibrahim N, et al : Neurocysticercosis in a Malaysian Muslim. Nerol J Southeast Asia 8 : 45-48, 2003.
 
4) Yanagida T, et al : Taeniasis and cysticercosis due to Taenia solium in Japan. Parasit Vectors 5 : 18, 2012.
PubMed
5) Yamasaki H : Current status and perspectives of cysticercosis and taeniasis in Japan. Korean J Parasitol 51 : 19-29, 2013.
 
6) Veliath AJ, et al : Cysticercosis in South India. J Trop Med Hyg 88 : 25-29, 1985.
PubMed
7) Scholtz L, Mentis H : Pulmonary cysticercosis. A case report. S Afr Med J 72 : 573-574, 1987.
PubMed
8) Choi JH, et al : A case of pulmonary cysticercosis. Korean J Intern Med 6 : 38-43. 1991.
PubMed
9) Bastos AL, et al : Pulmonary and cardiac cysticercosis : helical CT findings. Br J Radiol 80 : e58-60, 2007.
PubMed
10) Chen Y, et al : Two cases of pulmonary cysticercosis manifesting as pleural effusion : case report and literature review : J Thorac Dis 9 : E677-E681, 2017.
PubMed
11) Mamere AE, et al : Disseminated cysticercosis with pulmonary involvement. J Thorac Imaging 19 : 109-111, 2004.
 
P.251 掲載の参考文献
1) Kamiya H, et al : A red fox, Vulpes vulpes shrencki, infected with Echinococcus multilocularis was introduced from Hokkaido Island, where E. multilocularis is endemic, to Aomori, northern part of the mainland Japan. Jpn J Infect Dis 56 : 180-181, 2003.
PubMed
2) Irie T, et al : High probability of pet dogs encountering the sylvatic cycle of Echinococcus multilocularis in a rural area in Hokkaido, Japan. J Vet Med Sci 81 : 1606-1608, 2019.
 
3) Nonaka N, et al : Echinococcus multilocularis infection in pet dogs in Japan. Vector Borne Zoonotic Dis 9 : 201-206, 2009.
PubMed
4) 八木欣平 : エキノコックス症 : 日本における多包虫症の実態と人獣共通感染症としてのこれからの課題. 医学のあゆみ 259 : 881-887, 2016.
Medical*Online
5) Mao T, et al : Pulmonary echinococcosis in China. J Thorac Dis 11 : 3146-3155, 2009.
 
6) Morar R, Feldman C : Pulmonary echinococcosis. Eur Respir J 21 : 1069-1077, 2003.
PubMed
7) Santivanez S, Garcia HH : Pulmonary cystic echinococcosis. Curr Opin Pulm Med 16 : 257-261, 2010.
PubMed
8) Aydin Y, et al : Miliary Lung Metastases in Echinococcus Muitilocularis Infection. Ann Thorac Surg 108 : e47, 2019.
PubMed
9) Hesse AAJ, et al : Parasitic infestations requiring surgical interventions. Semin Pediatr Surg 21 : 142-150, 2012. (DOI : 10.1053/j.sempedsurg.2012.01.009)
 
10) Guo H, et al : Extrahepatic alveolar echinococcus on multi-slice computed tomography and magnetic resonance imaging. Sci Rep 11 : 9409, 2021. (DOI : 10.1038/s41598-021-89101-x)
 
11) Brunetti E, et al : Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans. Acta Trop 114 : 1-16, 2010.
PubMed
12) Greimelmaier K, et al : Pulmonary echinococcosis : A rare pseudotumour of the lung. Rare Tumors, 2021. (DOI : 10.1177/20363613211009769)
 
13) Mrgan M, Rytter D : [Liposarcoma in the lung misinterpreted as an infection of Echinococcus multicularis]. Ugeskr Laeger 176 : V01130061, 2014.
PubMed
14) 伊藤亮, 迫康仁 : 免疫学的検査/C. 感染症-抗原・抗体・遺伝子検査/抗エキノコックス抗体. 臨床検査ガイド 2013～2014 (Medical Practice編集委員会編), 文光堂, 2013.
 
15) Mihmanli M, et al : Current status of diagnosis and treatment of hepatic echinococcosis. World J Hepatol 8 : 1169-1181, 2016.
PubMed
16) Hesse AA, et al : Parasitic infestations requiring surgical interventions. Semin Pediatr Surg 21 : 142-150, 2012.
PubMed
17) Lupia T, et al : Pulmonary Echinococcosis or Lung Hydatidosis : A Narrative Review. Surg Infect (Larchmt) 22 : 485-495, 2021.
PubMed
P.256 掲載の参考文献
1) 高原豊ほか : 膿胸掻爬術を施行したPropionibacterium acnes膿胸の1例. 日本呼吸器学会雑誌 8 : 250-254, 2019.
 
2) Kononen E, Wade WG : Actinomyces and related organisms in human infections. Clin Microbiol Rev 28 : 419-442, 2015.
PubMed
3) Russo TO : Agents of Actinomycosis. In : Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 9th edition (ed by Bennett JE, et al), p3071-3081, Elsevier, Philadelphia, 2020.
 
4) Steininger C, Willinger B : Resistance patterns in clinical isolates of pathogenic Actinomyces species. J Antimicrob Chemother 71 : 422-427, 2016.
PubMed
5) Kobashi Y, et al : Thoracic actinomycosis with mainly pleural involvement. J Infect Chemother 10 : 172-177, 2004.
PubMed
6) 齊藤華子, ほか : 特徴ある胸部MRI所見を呈した肺放線菌症の1例. 日本呼吸器学会雑誌 41 : 276-281, 2003.
Medical*Online
7) Kim TS, et al : Thoracic Actinomycosis : CT Features with Histopathologic Correlation. AJR Am J Roentgenol 186 : 225-231, 2006.
PubMed
8) Himeji D, et al : Pulmonary Actinomyces graevenitzii Infection Diagnosed by Bronchoscopy using Endobronchial Ultrasonography with a Guide Sheath. Intern Med 57 : 2547-2551, 2018.
PubMed
9) 沖良生, ほか : 経気管支肺生検にて診断しえた肺放線菌症の1例. 日本呼吸器学会雑誌 41 : 202-206, 2003.
Medical*Online
10) 有村保次, ほか : 気管支鏡にて菌塊を証明しえた肺放線菌症の1例. 気管支学 27 : 131-135, 2005.
Medical*Online
11) 矢口大三, ほか : EBUS-TBNAが診断に有用であった肺放線菌症の1例. 気管支学 37 : 63-69, 2015.
Medical*Online
12) 洲崎賢太郎, ほか : 硫黄顆粒の喀出により診断し得たActinomyces odontolyticusおよびActinomyces meyeriによる肺放線菌症の1例. 日本呼吸器学会雑誌 43 : 231-235, 2005.
Medical*Online
13) 江田はるか, ほか : 16S rRNA解析により起因菌を確認し得た肺放線菌症の1例. 日本内科学会雑誌 107 : 2162-2169, 2018.
 
14) 石黒卓, ほか : Capnocytophaga sp. とActinomyces israeliiによる膿胸の1例. 日呼吸器学会雑誌 47 : 906-911, 2009.
 
15) Barberis C, et al : Antimicrobial susceptibility of clinical isolates of Actinomyces and related genera reveals an unusual clindamycin resistance among Actinomyces urogenitalis strains. J Glob Antimicrob Resist 8 : 115-120, 2017.
PubMed
16) Fong P, et al : Identification and diversity of Actinomyces species in a clinical microbiology laboratory in the MALDI-TOF MS era. Anaerobe 54 : 151-158, 2018.
 
P.262 掲載の参考文献
1) Miyashita N, Matsumoto A : Morphology of Chlamydia pneumoniae. In : Chlamydia pneumoniae Infection and Disease (ed by Friedman H, et al), p11-28, Springer, Boston, 2005
 
2) Miyashita N, et al : The morphology of Chlamydia pneumoniae. J Med Microbiol 38 : 418-425, 1993.
PubMed
3) Miyashita N, et al : Seroepidemiology of Chlamydia pneumoniae in Japan between 1991 and 2000. J Clin Pathol 55 : 115-117, 2002.
PubMed
4) Miyashita N, et al : Chlamydia pneumoniae and exacerbations of asthma in adults. Ann Allergy Asthma Immunol 80 : 405-409, 1998.
PubMed
5) Miyashita N, et al : Chlamydia pneumoniae infection in patients with diffuse panbronchiolitis and COPD. Chest 114 : 969-971, 1998.
PubMed
6) Miyashita N, et al : Antibody responses of Chlamydophila pneumoniae pneumonia : Why is the diagnosis of C. pneumoniae pneumonia difficult? J Infect Chemother 21 : 497-501, 2015.
 
P.266 掲載の参考文献
1) Hamdi AM, et al : Retrospective Analysis of Antimicrobial Susceptibility Profiles of Nocardia Species from a Tertiary Hospital and Reference Laboratory, 2011 to 2017. Antimicrob Agents Chemother 64 : 2020.
PubMed
2) Valdezate S, et al : Epidemiology and susceptibility to antimicrobial agents of the main Nocardia species in Spain. J Antimicrob Chemother 72 : 754-761, 2017.
 
3) Welsh O, et al : Current treatment for nocardia infections. Expert Opin Pharmacother 14 : 2387-2398, 2013.
PubMed
4) Yamaguchi H, et al : An autopsy case of disseminated nocardiosis involving multiple organs associated with chemotherapy-induced lung damage following lung cancer surgery. J St Marianna Univ 5 : 131-138, 2014.
 
5) Kanne JP, et al : CT findings of pulmonary nocardiosis. AJR Am J Roentgenol 197 : W266-272, 2011.
PubMed
6) Shariff M, Gunasekaran J : Pulmonary nocardiosis : Review of cases and an undate. Can Respir J 2016 : 7494202, 2016.
 
7) Wilson JW : Nocardiosis : updates and clinical overview. Mayo Clin Proc 87 : 403-407, 2012.
PubMed
8) Yazawa K, et al : In-vitro activity of new carbapenem antibiotics : comparative studies with meropenem, L-627 and imipenem against pathogenic Nocardia spp. J Antimicrob Chemother 29 : 169-172, 1992.
PubMed
9) Schlaberg R, et al : Susceptibility profiles of Nocardia isolates based on current taxonomy. Antimicrob Agents Chemother 58 : 795-800, 2014.
PubMed
10) Toyokawa M, et al : Identification and antimicrobial susceptibility profiles of Nocardia species clinically isolated in Japan. Sci Rep 11 : 16742, 2021.
PubMed
P.270 掲載の参考文献
1) Saraya T : The History of Mycoplasma pneumoniae Pneumonia. Front Microbiol 7 : 364, 2016.
PubMed
2) Saraya T, et al : Identification of a mechanism for lung inflammation caused by Mycoplasma pneumoniae using a novel mouse model. Results Immunol 1 : 76-87, 2011.
 
3) Saraya T, et al : Novel aspects on the pathogenesis of Mycoplasma pneumoniae pneumonia and therapeutic implications. Front Microbiol 5 : 410, 2014.
PubMed
4) Goto H : Multicenter surveillance of adult atypical pneumonia in Japan : its clinical features, and efficacy and safety of clarithromycin. J Infect Chemother 17 : 97-104, 2011.
PubMed
5) Saraya T, et al : Correlation between clinical features, high-resolution computed tomography findings, and a visual scoring system in patients with pneumonia due to Mycoplasma pneumoniae. Respir Investig 56 : 320-325, 2018.
 
6) Saraya T, et al : The Correlation between Chest X-ray Scores and the Clinical Findings in Children and Adults with Mycoplasma pneumoniae Pneumonia. Intern Med 56 : 2845-2849, 2017.
PubMed
7) Saraya T : Mycoplasma pneumoniae infection : Basics. J Gen Fam Med 18 : 118-125, 2017.
PubMed
8) Halm EA, et al : Time to clinical stability in patients hospitalized with community-acquired pneumonia : implications for practice guidelines. JAMA 279 : 1452-1457, 1998.
PubMed
9) Nir-Paz R, et al : Editorial : Mycoplasma pneumoniae Clinical Manifestations, Microbiology, and Immunology. Front Microbiol 8 : 1916, 2017.
PubMed
P.275 掲載の参考文献
1) 山藤栄一郎 : リケッチア感染症. 日本紅斑熱とツツガムシ病をどのように疑い, 診断・治療するか. Hospitalist 5 : 519-528, 2017.
 
2) 安藤匡子 : Q熱 (コクシエラ症) 起因菌Coxiella burnetiiの最近の知見. モダンメディア 55 : 59-69, 2009.
 
3) 渡辺彰 : Q熱診療の最前線. 日本内科学会誌 97 : 423-429, 2008.
 
4) 岩崎博道, ほか : 我が国におけるリケッチア感染症の現状と課題. 日本内科学会誌 108 : 1866-1872, 2019.
 
5) 岩崎博道 : リケッチア症診療の手引き～つつが虫病と日本紅斑熱～, 2019. 福井大学医学部附属病院・感染症膠原病内科. [https://www.hosp.u-fukui.ac.jp/department/infection/]
 
6) Iwasaki H, et al : Fulminant Rickettsia tsutsugamushi infection associated with haemophagocytic syndrome. Lancet 343 : 1236, 1994.
PubMed
7) Jeong YJ, et al : Scrub typhus : clinical, pathologic, and imaging findings. Radiographics 27 : 161-172, 2007.
PubMed
8) Iwasaki H, et al : Increased levels of macrophage colony-stimulating factor, gamma interferon, and tumor necrosis factor alpha in sera of patients with Orientia tsutsugamushi infection. J Clin Microbiol 35 : 3320-3322, 1997.
PubMed
9) Matsuura H : Japanese spotted fever and rickettsial pneumonia. QJM 114 : 261-262, 2021.
PubMed
10) Iwasaki H, et al : Fulminant Japanese spotted fever associated with hypercytokinemia. J Clin Microbiol 39 : 2341-2343, 2001.
PubMed
11) Tai K, et al : Significantly higher cytokine and chemokine levels in patients with Japanese spotted fever than in those with Tsutsugamushi disease. J Clin Microbiol 52 : 1938-1946, 2014.
 
12) von Ranke FM, et al : Acute Q fever pneumonia : high-resolution computed tomographic findings in six patients. Br J Radiol 92 : 20180292, 2019.
PubMed
13) Ikegaya S, et al : Tsutsugamushi disease caused by Shimokoshi-type Orientia tsutsugamushi : the first report in Western Japan. Am J Trop Med Hyg 88 : 1217-1219, 2013.
PubMed
14) Iwasaki H, et al : The mechanism of severity of tsutsugamushi disease (scrub typhus) in Asia. Res Adv Microbiol 3 : 131-137, 2003.
 
P.280 掲載の参考文献
1) 厚生労働省健康局結核感染症課 : 一類感染症への行政対応の手引き (案). [https://www.mhlw.go.jp/content/10906000/000485755.pdf]
 
2) CDC ; Centers for Disease Control and Prevention : Plague, Information for Healthcare Professionals, Resources for Clinicians. [https://www.cdc.gov/plague/healthcare/clinicians.html]
 
3) Boulanger LL, et al : Gentamicin and tetracyclines for the treatment of human plague : review of 75 cases in new Mexico, 1985-1999. Clin Infect Dis 38 : 663-669, 2004.
PubMed
4) Mwengee W, et al : Treatment of plague with gentamicin or doxycycline in a randomized clinical trial in Tanzania. Clin Infect Dis 42 : 614-621, 2006.
PubMed
P.285 掲載の参考文献
1) 丸山務, 景森令克 : イヌ・ネコの咬傷・掻傷に起因するヒトのパスツレラ症. 日本獣医師会雑誌 35 : 621-626, 1982.
 
2) 荒島康友, ほか : 1992-2001年の10年間の本邦におけるPasteurella spp. の分離状況. 獣医畜産新報 57 : 667-668, 2004.
 
3) Drabick JJ, et al : Pasteurella multocida pneumonia in a man with AIDS and nontraumatic feline exposure. Chest 103 : 7-11, 1993.
 
4) Arashima Y, et al : A first case of abnormal sensation in the throat caused by Pasteurella canis. Int Med J 20 : 701-702, 2013.
 
5) 荒島康友, 矢久保修嗣 : 新世紀・「One Health」としてのZoonosis <第6回> Zoonosis 各論 2. Pasteurella症 総論. 大塚薬報 669 : 28-31, 2011.
 
6) 西岡みどり, ほか : Parella multocidaによる肺炎成人患者における伴侶動物との日常生活 : 症例報告の検討. 国立看護大学校研究紀要 16 : 35-39, 2017.
 
7) 石黒卓, ほか : パスツレラ呼吸器感染症の臨床的検討. 日本呼吸器学会誌 6 : 144-149, 2017.
Medical*Online
8) 杉野安輝, ほか : 人獣感染を分子疫学的に証明し得たPasteurella multocida肺炎の1例. 感染症誌 81 : 726-730, 2007.
 
9) 宮下琢, ほか : パスツレラ肺炎. 別冊日本臨床新領域別症候群シリーズ No. 8 呼吸器症候群 (第2版) I, p271-274, 日本臨牀社, 2008.
 
10) 正木康晶, ほか : 肺結核との鑑別を要したPasteurella multocida肺感染症の1例. 気管支学 39 : 318-321, 2016.
 
11) Myers EM, et al : Life-threatening respiratory pasteurellosis associated with palliative pet care. Clin Infect Dis 54 : e55-57, 2012.
PubMed
P.289 掲載の参考文献
1) 藤田博己 : 野兎病. モダンメディア 50 : 99-103, 2004.
 
2) World Health Organization : WHO guidelines on tularemia. World Health Organization, Geneva, 2007. [https://apps.who.int/iris/handle/10665/43793]
 
3) Ohara Y, et al : Epidemiological analysis of tularemia in Japan (yato-byo). FEMS Immunol Med Microbiol 13 : 185-189, 1996.
PubMed
4) Lyons CR, Wu TH : Animal models of Francisella tularensis infection. In Francisella tularensis : Biology, Pathogenicity, Epidemiology, and Biodefense (ed by Kwaik YA, et al), p238-265, Blackwell publishing on behalf of Ann N Y Acad Sci, Boston. 2007.
 
5) Eden JS, et al : Francisella tularensis ssp. holarctica in Ringtail Possums, Australia. Emerg Infect Dis 23 : 1198-1201, 2017.
PubMed
6) Hotta A, et al : Survey of Francisella tularensis in Wild Animals in Japan in Areas Where Tularemia is Endemic. Jpn J Infect Dis 69 : 431-434, 2016.
PubMed
7) Friend M : Tularemia. U. S. Geological Suevey, Circular 1297. (online) [https://pubs.usgs.gov/circ/1297/report.pdf]
 
8) Dennis DT, et al : Tularemia as a biological weapon : medical and public health management. JAMA 285 : 2763-2773, 2001.
PubMed
9) Saslaw S, et al : Tularemia vaccine study. II. Respiratory challenge. Arch Intern Med 107 : 702-714, 1961.
PubMed
10) Hornick RB, Eigelsbach HT : Aerogenic immunization of man with live Tularemia vaccine. Bacteriol Rev 30 : 532-538, 1966.
PubMed
11) Bellido-Casado J, et al : Report on five cases of tularaemic pneumonia in a tularaemia outbreak in Spain. Eur J Clin Microbiol Infect Dis 19 : 218-220, 2000.
 
12) Ohara Y, et al : Clinical manifestations of tularemia in Japan-analysis of 1,355 cases observed between 1924 and 1987. Infection 19 : 14-17, 1991.
 
13) 朴天鎬, ほか : 野兎病菌に自然感染したトウホクノウサギ (Lepus brachyurus angustidens) の症例-野生動物の病理解剖の意義と感染リスク-. 獣医畜産新報 63 : 197-200, 2010.
 
14) Su TY, et al : Case Report of Low Virulence Francisella tularensis Presented as Severe Bacteremic Pneumonia. Medicine (Baltimore) 95 : e3390, 2016.
PubMed
15) Tarnvik A, Chu MC : New approaches to diagnosis and therapy of tularemia. In : Francisella tularensis : Biology, Pathogenicity, Epidemiology, and Biodefense (ed by Kwaik YA, et al), p378-404, Blackwell publishing on behalf of Ann N Y Acad Sci, Boston, 2007.
 
P.294 掲載の参考文献
1) Corbel MJ : Brucellosis in humans and animals. WHO/CDS/EPR/2006. 7, WHO, 2006. [https://www.who.int/csr/resources/publications/Brucellosis.pdf]
 
2) CDC : Centers for Disease Control and Prevention : Brucellosis, 2021. [https://www.cdc.gov/brucellosis/]
 
3) 国立感染症研究所 : 特集ブルセラ症 1999年4月～2012年3月. 病原微生物検出情報 33 : 183-184, 2012. [https://www.niid.go.jp/niid/ja/brucella-m/brucella-iasrtpc/2342-tpc389-j.html]
 
4) 今岡浩一 : ブルセラ症の現状と対応. 感染症TODAY・ラジオNIKKEI, 2019. [http://medical.radionikkei.jp/kansenshotoday/ondemand/kansenshotoday-190109.html]
 
5) Madkour MM, Al-Saif A : Respiratory Brucellosis. In : Madkour's Brucellosis (ed by Madkour MM), p144-149, Springer-Verlag, Berlin, 2001.
 
6) Solera J, et al : Treatment of pulmonary brucellosis : a systematic review. Expert Rev Anti Infect Ther 15 : 33-42, 2017.
PubMed
7) LPSN. dsmz. de : Genus Brucella. [https://lpsn.dsmz.de/genus/brucella]
 
8) 平井潤, ほか : Ochrobactrum intermedium菌血症の1例. 感染症学雑誌 90 : 129-133, 2016.
 
9) Erdem H, et al : Respiratory system involvement in brucellosis : the results of the Kardelen study. Chest 145 : 87-94, 2014.
PubMed
10) Pappas G, et al : Brucellosis and the respiratory system. Clin Infect Dis 37 : e95-99, 2003.
PubMed
11) Hatipoglu CA, et al : Pulmonary involvement in brucellosis. J Infect 51 : 116-119, 2005.
PubMed
12) Sewell DL : Laboratory-associated infections and biosafety. Clin Microbiol Rev 8 : 389-405, 1995.
PubMed
13) Vila A, et al : Brucella suis bacteremia misidentified as Ochrobactrum anthropi by the VITEK 2 system. J Infect Dev Ctries 28 : 432-436, 2016.
 
14) Poonawala H, et al : The Brief Case : Misidentification of Brucella melitensis as Ochrobactrum anthropi by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS). J Clin Microbiol 56 : e00914-00917, 2018.
 
15) Skalsky K, et al : Treatment of human brucellosis : systematic review and meta-analysis of randomized controlled trials. BMJ 336 : 701-704, 2008.
PubMed
P.298 掲載の参考文献
1) Mendelson CL : The aspiration of stomach contents into the lungs during obstetric anesthesia. Am J Obstet Gynecol 52 : 191-205, 1946.
PubMed
2) Holmes N, et al : Cricoid pressure : a review of the literature. J Perioper Pract 21 : 234-238, 2011.
PubMed
3) Sellick BA : Cricoid pressure to control regurgitation of stomach contents during induction of anaesthesia. Lancet 2 : 404-406, 1961.
PubMed
4) 福地義之助 : 老人の肺炎と誤嚥. CLINICIAN 44 : 973-978, 1997.
 
5) Engelhardt T, Webster NR : Pulmonary aspiration of gastric contents in anaesthesia. Br J Anaesth 83 : 453-460, 1999.
PubMed
6) 福井麻里子, ほか : 肺癌術後気管支鏡を契機にMendelson症候群をきたした一例. 日本呼吸器外科学会雑誌 34 : 666-670, 2020.
 
7) Cameron JL, et al : Aspiration pneumonia : physiologic data following experimental aspiration. Surgery 72 : 238-245, 1972.
PubMed
8) Broe PJ, et al : Aspiration pneumonia. Surg Clin North Am 60 : 1551-1564, 1980.
PubMed
9) Wolfe JE, et al : Effects of corticosteroids in the treatment of patients with gastric aspiration. Am J Med 63 : 719-722, 1977.
PubMed
10) Schneck H, et al : Anesthesia for cesarean section and acid aspiration prophylaxis : a German survey. Anesth Analg 88 : 63-66, 1999.
 
11) Birenbaum A, et al : Effect of Cricoid Pressure Compared With a Sham Procedure in the Rapid Sequence Induction of Anesthesia : The IRIS Randomized Clinical Trial. JAMA Surg 154 : 9-17, 2019.
PubMed
P.300 掲載の参考文献
1) Keane MA, et al : Wandering consolidation. Postgrad Med J 71 : 685-686, 1995.
PubMed
2) Yoshida Y, et al : Wandering Pneumonia Mimicked by COVID-19. Intern Med 60 : 493-494, 2021.
PubMed
P.314 掲載の参考文献
1) エイズ予防情報ネット : エイズ動向委員会年報 [https://api-net.jfap.or.jp/status/japan/nenpo.html]
 
2) 日本医療研究開発機構 エイズ対策実用化研究事業「ART早期化と長期化に伴う日和見感染症への対処に関する研究」班 : アンケート結果 日本におけるHIV感染症に伴う日和見合併症の動向-2019年症例分解析-. [http://after-art.umin.jp/enq_hiyorimi.html]
 
3) 厚生労働行政推進調査事業費補助金 (エイズ対策政策研究事業) HIV感染症及びその合併症の課題を克服する研究班 : 抗HIV治療ガイドライン (2021年3月発行). [https://www.haart-support.jp/guideline.htm]
 
P.317 掲載の参考文献
1) Byerley JS, et al : Clinical approach to endogenous lipoid pneumonia. Clin Respir J 10 : 259-263, 2016.
PubMed
2) Beck LR, Landsberg D : Lipoid Pneumonia. StatPearls. Treasure Island (FL), StatPearls Publishing, 2021.
 
3) Volk BW, et al : Incidence of lipoid pneumonia in a survey of 389 chronically ill patients. Am J Med 10 : 316-324, 1951.
 
4) Gondouin A, et al : Exogenous lipid pneumonia : a retrospective multicentre study of 44 cases in France. Eur Respir J 9 : 1463-1469, 1996.
PubMed
5) Samhouri BF, et al : Presenting Clinicoradiologic Features, Causes, and Clinical Course of Exogenous Lipoid Pneumonia in Adults. Chest 160 : 624-632, 2021.
PubMed
6) Marchiori E, et al : Exogenous lipoid pneumonia. Clinical and radiological manifestations. Respir Med 105 : 659-666, 2011.
PubMed
7) Davidson K, et al : Outbreak of Electronic-Cigarette-Associated Acute Lipoid Pneumonia-North Carolina, July-August 2019. MMWR Morb Mortal Wkly Rep 68 : 784-786, 2019.
PubMed
8) Smith ML, et al : Vaping-related lung injury. Virchows Arch 478 : 81-88, 2021.
PubMed
9) Hadda V, Khilnani GC : Lipoid pneumonia : an overview. Expert Rev Respir Med 4 : 799-807, 2010.
PubMed
10) Marchiori E, et al : Lipoid pneumonia in 53 patients after aspiration of mineral oil : comparison of high-resolution computed tomography findings in adults and children. J Comput Assist Tomogr 34 : 9-12, 2010.
 
11) Laurent F, et al : Exogenous lipoid pneumonia : HRCT, MR, and pathologic findings. Eur Radiol 9 : 1190-1196, 1999.
PubMed
12) Shang L, et al : The efficacy and safety of therapeutic lung lavage for exogenous lipoid pneumonia : A systematic review. Clin Respir J 15 : 134-146, 2021.
PubMed
P.322 掲載の参考文献
1) 河端美則 : 治療反応性を考慮に入れた間質性肺炎の分類-急性, 亜急性例の位置づけ-. 呼吸 15 : 132-137, 1996.
Medical*Online
2) Cordier JF : Cryptogenic organising pneumonia, Eur Respir J 28 : 422-446, 2006.
PubMed
3) Mukhopadhyay S : Predominantly Interstitial lung disease. In : Non-Neoplastic Pulmonary Pathology, p210-211, UK : Cambridge University Press, 2016.
 
4) Kligerman SJ, et al : From the radiologic pathology archives : organization and fibrosis as a response to lung injury in diffuse alveolar damage, organizing pneumonia, and acute fibrinous and organizing pneumonia. Radiographics 33 : 1951-1975, 2013.
PubMed
5) Feinstein MB, et al : A comparison of the pathological, clinical and radiographical, features of cryptogenic organising pneumonia, acute fibrinous and organising pneumonia and granulomatous organising pneumonia. J Clin Pathol 68 : 441-447, 2015.
PubMed
6) Beasley MB, et al : Acute fibrinous and organizing pneumonia : a histological pattern of lung injury and possible variant of diffuse alveolar damage. Arch Pathol Lab Med 126 : 1064-1070, 2002.
PubMed
7) Park J, et al : Histopathologic heterogeneity of acute respiratory distress syndrome revealed by surgical lung biopsy and its clinical implications. Korean J Intern Med 33 : 532-540, 2018.
PubMed
8) Yousem SA : Cicatricial variant of cryptogenic organizing pneumonia. Hum Pathol 64 : 76-82, 2017.
PubMed
9) Torrealba JR, et al : Pathology-radiology correlation of common and uncommon computed tomographic patterns of organizing pneumonia. Hum Pathol 71 : 30-40, 2018.
PubMed
10) Enomoto N, et al : Clinical, radiological, and pathological evaluation of "NSIP with OP overlap" pattern compared with NSIP in patients with idiopathic interstitial pneumonias. Respir Med 174 : 106201, 2020.
PubMed
11) Lee JW, et al : Cryptogenic organizing Pneumonia : serial high-resolution CT findings in 22 patients. AJR Am J Roentgenol 195 : 916-922, 2010.
PubMed
12) Maldonado F, et al : Focal organizing pneumonia on surgical lung biopsy : causes, clinicoradiologic features, and outcomes. Chest 132 : 1579-1583, 2007.
PubMed
13) Drakopanagiotakis F, et al : Cryptogenic and secondary organizing pneumonia : clinical presentation, radiographic findings, treatment response, and prognosis. Chest 139 : 893-900, 2011.
PubMed
P.328 掲載の参考文献
1) 成人肺炎診療ガイドライン 2017 (日本呼吸器学会成人肺炎診療ガイドライン2017作成委員会編), 一般社団法人日本呼吸器学会, 2017.
 
2) Marin-Corral J, et al : Aspiration Risk Factors, Microbiology, and Empiric Antibiotics for Patients Hospitalized With Community-Acquired Pneumonia. Chest 159 : 58-72, 2021.
PubMed
P.335 掲載の参考文献
1) Teramoto S, et al : Update on the pathogenesis and management of pneumonia in the elderly-roles of aspiration pneumonia. Respir Investig 53 : 178-184, 2015.
PubMed
2) Kikuchi R, et al : High incidence of silent aspiration in elderly patients with community-acquired pneumonia. Am J Respir Crit Care Med 150 : 251-253, 1994.
PubMed
3) 日本呼吸器学会呼吸器感染症に関するガイドライン作成委員会 (編) : 第IX章 誤嚥性肺炎, 成人院内肺炎診療ガイドライン, 一般社団法人日本呼吸器学会, 2008.
 
4) 医療・介護関連肺炎診療ガイドライン (医療・介護関連肺炎 (NHCP) 診療ガイドライン作成委員会編), 一般社団法人日本呼吸器学会, 2012. [https://www.jrs.or.jp/uploads/uploads/files/photos/1050.pdf]
 
5) 成人肺炎診療ガイドライン 2017 (日本呼吸器学会成人肺炎診療ガイドライン2017作成委員会編), 一般社団法人日本呼吸器学会, 2017. [https://www.jrs.or.jp/modules/guidelines/index.php?content_id=94]
 
6) 嚥下性肺疾患の診断と治療 [改訂版] (嚥下性肺疾患研究会編), ファイザー, 2013.
 
7) Teramoto S, et al : High incidence of aspiration pneumonia in community- and hospital-acquired pneumonia in hospitalized patients : a multicenter, prospective study in Japan. J Am Geriatr Soc 56 : 577-579, 2008.
PubMed
8) 厚生労働省大臣官房統計情報部 : 「人口動態統計」「疾病, 傷害及び死因の統計分類」 令和2年度. [https://www.mhlw.go.jp/toukei/sippei/]
 
9) Yamaya M, et al : Interventions to prevent pneumonia among older adults. J Am Geriatr Soc 49 : 85-90, 2001.
PubMed
10) Ohkubo T, et al : Effects of an angiotensin-converting enzyme inhibitor-based regimen on pneumonia risk. Am J Respir Crit Care Med 169 : 1041-1045, 2004.
PubMed
11) Teramoto S, et al : ACE inhibitors prevent aspiration pneumonia in Asian, but not Caucasian, elderly patients with stroke. Eur Respir J 29 : 218-219 ; author reply 219-220, 2007.
PubMed
12) Shinohara Y : Antiplatelet cilostazol is effective in the prevention of pneumonia in ischemic stroke patients in the chronic stage. Cerebrovasc Dis 22 : 57-60, 2006.
PubMed
13) Momosaki R, et al : Effect of early rehabilitation by physical therapists on in-hospital mortality after aspiration pneumonia in the elderly. Arch Phys Med Rehabil 96 : 205-209, 2015.
PubMed
P.340 掲載の参考文献
1) American Thoracic Society, et al : Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171 : 388-416, 2005.
PubMed
2) Shindo Y, et al : Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia. Am J Respir Crit Care Med 188 : 985-995, 2013.
PubMed
3) Ewig S, et al : Rethinking the concepts of community-acquired and health-care-associated pneumonia. Lancet Infect Dis 10 : 279-287, 2010.
PubMed
4) Metlay Jp, et al : Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 200 : e45-e67, 2019.
 
5) Torres A, et al : International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia : Guidelines for the management of hospital-acquired pneumonia (HAP) /ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociacion Latinoamericana del Torax (ALAT). Eur Respir J 50 : 1700582, 2017.
PubMed
6) Kalil AC, et al : Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia : 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 63 : e61-e111, 2016.
 
7) 成人肺炎診療ガイドライン 2017 (日本呼吸器学会成人肺炎診療ガイドライン2017作成委員会編), 一般社団法人日本呼吸器学会, 2017.
 
8) Shindo Y, et al : Comparison of severity scoring systems A-DROP and CURB-65 for community-acquired pneumonia. Respirology 13 : 731-735, 2008.
PubMed
9) Shindo Y, et al : Regional differences in antibiotic-resistant pathogens in patients with pneumonia : Implications for clinicians. Respirology 22 : 1536-1546, 2017.
PubMed
P.347 掲載の参考文献
1) Scoggin CH, et al : Status asthmaticus. A nine-year experience. JAMA 238 : 1158-1162, 1977.
PubMed
2) Kalil AC, et al : Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia : 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 63 : e61-e111, 2016.
 
3) 日本呼吸器学会, ほか : ARDS診療ガイドライン 2016 (3学会合同ARDS診療ガイドライン2016作成委員会編), 日本呼吸器学会/日本呼吸療法医学会/日本集中治療医学会, 2016. [https://www.jsicm.org/pdf/ARDSGL2016.pdf]
 
4) 厚生労働省院内感染対策サーベイランス事業. [https://janis.mhlw.go.jp]
 
5) Zhao T, et al : Oral hygiene care for critically ill patients to prevent ventilator-associated pneumonia. Cochrane Database Syst Rev 12 : CD008367, 2020.
PubMed
6) Heyland DK, et al : Canadian clinical practice guidelines for nutrition support in mechanically ventilated, critically ill adult patients. JPEN J Parenter Enteral Nutr 27 : 355-373, 2003.
PubMed
7) Chen S, et al : Trends and development in enteral nutrition application for ventilator associated pneumonia : A scientometric research study (1996-2018). Front Pharmacol 10 : 246, 2019.
PubMed
8) 松田直之, ほか : 敗血症性多臓器不全に対する遺伝子治療～Alert Cell Strategy～. 実験医学 (増刊) 31 : 773-779, 2013.
 
9) Elliott D, et al : Incidence of ventilator-associated pneumonia in Australasian intensive care units : use of a consensus-developed clinical surveillance checklist in a multisite prospective audit. BMJ Open 5 : e008924, 2015.
 
10) Alessandri F, et al : Procalcitonin in the Assessment of Ventilator Associated Pneumonia : A Systematic Review. Adv Exp Med Biol 1323 : 103-114, 2020.
PubMed
11) Burja S, et al : Efficacy of a bundle approach in preventing the incidence of ventilator associated pneumonia (VAP). Bosn J Basic Med Sci 18 : 105-109, 2018.
PubMed
12) 日本版敗血症診療ガイドライン 2020. 日本集中治療医学会雑誌 28 (Suppl) : S1-S411, 2011. [https://www.jsicm.org/pdf/jjsicm28Suppl.pdf]
 
13) Kosinski S, et al : What Is Post-Intensive Care Syndrome (PICS)? Am J Respir Crit Care Med 201 : P15-P16, 2020.
PubMed
P.353 掲載の参考文献
1) Bertelsen S, et al : Isolated middle lobe atelectasis : aetiology, pathogenesis, and treatment of the so-called middle lobe syndrome. Thorax 35 : 449-452, 1980.
PubMed
2) Gudbjartsson T, Gudmundsson G : Middle lobe syndrome : a review of clinicopathological features, diagnosis and treatment. Respiration 84 : 80-86, 2012.
PubMed
3) Shaikh U, Heller D : Right middle lobe syndrome. StatPearls Publishing, 2021. [https://www.statpearls.com/ArticleLibrary/viewarticle/28598]
 
4) Prince DS, et al : Infection with Mycobacterium avium complex in patients without predisposing conditions. N Engl J Med 321 : 863-868, 1989.
PubMed
5) Reich JM, Johnson RE : Mycobacterium avium complex pulmonary disease presenting as an isolated lingular or middle lobe pattern. The Lady Windermere syndrome. Chest 101 : 1605-1609, 1992.
PubMed
6) Graham EA, et al : Middle lobe syndrome. Postgrad Med 4 : 29-34, 1948.
PubMed
7) Camishion RC, et al : Isolated disease of the middle lobe and lingula. Dis Chest 50 : 67-71, 1966.
PubMed
8) Wagner RB, Johnston MR : Middle lobe syndrome. Ann Thorac Surg 35 : 679-686, 1983.
PubMed
9) Culiner MM : The right middle lobe syndrome, a non-obstructive complex. Dis Chest 50 : 57-66, 1966.
PubMed
10) Levin DL : Radiology of pulmonary Mycobacterium avium-intracellulare complex. Clin Chest Med 23 : 603-612, 2002.
PubMed
11) Einarsson JT, et al : Middle lobe syndrome : a nationwide study on clinicopathological features and surgical treatment. Clin Respir J 3 : 77-81, 2009.
 
12) Berrocal T, et al : Congenital anomalies of the tracheobronchial tree, lung, and mediastinum : embryology, radiology, and pathology. Radiographics 24 : e17, 2004.
PubMed
13) Terry PB, et al : The Clinical Significance of Collateral Ventilation. Ann Am Thorac Soc 13 : 2251-2257, 2016.
PubMed
14) Polverino E, et al : European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J 50 : 2017.
PubMed
15) Gudmundsson G, Gross TJ : Middle lobe syndrome. Am Fam Physician 53 : 2547-2550, 1996,
PubMed
16) Javidan-Nejad C, Bhalla S : Bronchiectasis. Radiol Clin North Am 47 : 289-306, 2009.
PubMed
17) Rashid A, et al : Infectious Causes of Right Middle Lobe Syndrome. Cancer Control 24 : 60-65, 2017.
PubMed
18) Shibata Y, et al : Diagnostic test accuracy of anti-glycopeptidolipid-core IgA antibodies for Mycobacterium avium complex pulmonary disease : systematic review and meta-analysis. Sci Rep 6 : 29325, 2016.
PubMed
19) Shah A, et al : Middle lobe syndrome : a rare presentation of allergic bronchopulmonary aspergillosis. Eur Ann Allergy Clin Immunol 46 : 147-151, 2014.
PubMed
20) Nadel HR, et al : The immotile cilia syndrome : radiological manifestations. Radiology 154 : 651-655, 1985.
PubMed
21) Priftis KN, et al : The role of timely intervention in middle lobe syndrome in children. Chest 128 : 2504-2510, 2005.
PubMed
22) Chalmers JD, et al : Long-term macrolide antibiotics for the treatment of bronchiectasis in adults : an individual participant data meta-analysis. Lancet Respir Med 7 : 845-854, 2019.
PubMed
23) Morimoto K, et al : Macrolide-resistant Mycobacterium avium complex lung disease : Analysis of 102 consecutive cases. Ann Am Thorac Soc 13 : 1904-1911, 2016.
PubMed
24) Daley CL, et al : Treatment of nontuberculous mycobacterial pulmonary disease : An official ATS/ERS/ESCMID/IDSA clinical practice guideline. Clin Infect Dis 71 : e1-e36, 2020.
PubMed
25) Ishikawa H, et al : Efficacy and safety of super selective bronchial artery coil embolisation for haemoptysis : a single-centre retrospective observational study. BMJ Open 7 : e014805, 2017.
PubMed
26) Omachi N, et al : The impact of bronchial artery embolisation on the quality of life of patients with haemoptysis : a prospective observational study. Eur Radiol 31 : 5351-5360, 2021.
PubMed
27) Corless JA, Warburton CJ : Surgery vs non-surgical treatment for bronchiectasis. Cochrane Database Syst Rev 2000 (4) : CD002180, 2000.
PubMed
28) Ayed AK : Resection of the right middle lobe and lingula in children for middle lobe/lingula syndrome. Chest 125 : 38-42, 2004.
PubMed
P.359 掲載の参考文献
1) Mandell LA, et al : Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44 (Suppl 2) : S27-72, 2007.
 
2) Menendez R, et al : Risk factors of treatment failure in community acquired pneumonia : implications for disease outcome. Thorax 59 : 960-965, 2004.
PubMed
3) Arancibia F, et al : Antimicrobial treatment failures in patients with community-acquired pneumonia : causes and prognostic implications. Am J Respir Crit Care Med 162 : 154-160, 2000.
PubMed
4) Halm EA, et al : Time to clinical stability in patients hospitalized with community-acquired pneumonia : implications for practice guidelines. JAMA 279 : 1452-1457, 1998.
PubMed
5) Mittl RL, et al : Radiographic resolution of community-acquired pneumonia Am J Respir Crit Care Med 149 : 630-635, 1994.
PubMed
6) Komiya K, et al : Prognostic implications of aspiration pneumonia in patients with community acquired pneumonia : A systematic review with meta-analysis. Sci Rep 6 : 38097, 2016.
PubMed
7) Komiya K, et al : Computed tomography findings of aspiration pneumonia in 53 patients. Geriatr Gerontol Int 13 : 580-585, 2013.
PubMed
8) Persson E, et al : Repetitive Saliva Swallowing Test : Norms, Clinical Relevance and the Impact of Saliva Secretion. Dysphagia 34 : 271-278, 2019.
PubMed
9) Al Zahrani K, et al : Yield of smear, culture and amplification tests from repeated sputum induction for the diagnosis of pulmonary tuberculosis. Int J Tuberc Lung Dis 5 : 855-860, 2001.
 
10) Goto A, et al : Factors associated with atypical radiological findings of pulmonary tuberculosis. PLoS One 14 : e0220346, 2019.
PubMed
11) Kitada S, et al : Serological test and chest computed tomography findings in patients with Mycobacterium avium complex lung disease. Eur Respir J 29 : 1217-1223, 2007.
PubMed
12) Arfaatabar M, et al : Rapid Detection of Mycoplasma pneumoniae by Loop-Mediated Isothermal Amplification (LAMP) in Clinical Respiratory Specimens. Iran J Public Health 48 : 917-924, 2019.
PubMed
13) Yoon SH, et al : Immunochromatography for the diagnosis of Mycoplasma pneumoniae infection : A systematic review and meta-analysis. PLoS One 15 : e0230338, 2020.
 
14) Watson J, et al : Interpreting a covid-19 test result. BMJ 369 : m1808, 2020.
PubMed
15) Karageorgopoulos DE, et al : β-D-glucan assay for the diagnosis of invasive fungal infections : a meta-analysis. Clin Infect Dis 52 : 750-770, 2011.
 
16) Del Corpo O, et al : Diagnostic accuracy of serum (1-3) -β-D-glucan for Pneumocystis jirovecii pneumonia : a systematic review and meta-analysis. Clin Microbiol Infect 26 : 1137-1143, 2020.
 
17) Komiya K, et al : Comparison of chest computed tomography features in the acute phase of cardiogenic pulmonary edema and acute respiratory distress syndrome on arrival at the emergency department. J Thorac Imaging 28 : 322-328, 2013.
PubMed
18) Komiya K, et al : A systematic review of diagnostic methods to differentiate acute lung injury/acute respiratory distress syndrome from cardiogenic pulmonary edema. Crit Care 21 : 228, 2017.
PubMed
19) Crawford F, et al : D-dimer test for excluding the diagnosis of pulmonary embolism. Cochrane Database Syst Rev 2016 : CD010864, 2016.
 
P.364 掲載の参考文献
1) Reimann HA : An acute infection of the respiratory tract with atypical pneumonia : a disease entity probably caused by a filtrable virus. JAMA 111 : 2377-2384, 1938.
 
2) Sarosi GA : "Atypical pneumonia". Why this term may be better left unsaid. Postgrad Med 105 : 131-138, 1999.
PubMed
3) Mandell LA, et al : Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44 (Suppl 2) : S27-72, 2007.
 
4) 成人肺炎診療ガイドライン 2017 (日本呼吸器学会成人肺炎診療ガイドライン2017作成委員会編), 一般社団法人日本呼吸器学会, 2017.
 
5) Arnold FW, et al : A worldwide perspective of atypical pathogens in community-acquired pneumonia. Am J Respir Crit Care Med 175 : 1086-1093, 2007.
PubMed
6) Capelastegui A, et al : Etiology of community-acquired pneumonia in a population-based study : link between etiology and patients characteristics, process-of-care, clinical evolution and outcomes. BMC Infect Dis 12 : 134, 2012.
 
7) Yamasaki K, et al : Significance of anaerobes and oral bacteria in community-acquired pneumonia. PLoS One 8 : e63103, 2013.
PubMed
8) Ishida T, et al : Clinical differentiation of atypical pneumonia using Japanese guidelines. Respirology 12 : 104-110, 2007.
PubMed
9) Yin YD, et al : Evaluation of the Japanese Respiratory Society guidelines for the identification of Mycoplasma pneumoniae pneumonia. Respirology 17 : 1131-1136, 2012.
 
10) Miyashita N, et al : Infiuence of age on the clinical differentiation of atypical pneumonia in adults. Respirology 17 : 1073-1079, 2012.
 
11) Hedlund J, Hansson LO : Procalcitonin and C-reactive protein levels in community-acquired pneumonia : correlation with etiology and prognosis. Infection 28 : 68-73, 2000.
 
12) Ito I, et al : Differentiation of bacterial and non-bacterial community-acquired pneumonia by thin-section computed tomography. Eur J Radiol 72 : 388-395, 2009.
PubMed
13) Miyashita N, et al : Radiographic features of Mycoplasma pneumoniae pneumonia : differential diagnosis and performance timing. BMC Med Imaging 9 : 7, 2009.
PubMed
14) Miyashita N, et al : Macrolide-resistant Mycoplasma pneumoniae pneumonia in adolescents and adults : clinical findings, drug susceptibility, and therapeutic efficacy. Antimicrob Agents Chemother 57 : 5181-5185, 2013.
PubMed
15) Valade S, et al : Severe atypical pneumonia in critically ill patients : a retrospective multicenter study. Ann Intensive Care 8 : 81, 2018.
PubMed
P.369 掲載の参考文献
1) 成人院内肺炎診療ガイドライン (日本呼吸器学会「呼吸器感染症に関するガイドライン作成委員会」編), 日本呼吸器学会, 2008.
 
2) 発熱性好中球減少症 (FN) 診療ガイドライン (日本臨床腫瘍学会編), 2012. [https://minds.jcqhc.or.jp/docs/minds/febrile-neutropenia/febrile-neutropenia-front-matter.pdf]
 
3) Aoshima M, et al : Two-exon skipping due to a point mutation in p67-phox--deficient chronic granulomatous disease. Blood 88 : 1841-1845, 1996.
PubMed
4) Komano Y, et al : Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors : a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety. J Rheumatol 38 : 1258-1264, 2011.
PubMed
5) Geri G, et al : Risk of infections in bronchiectasis during disease-modifying treatment and biologics for rheumatic diseases. BMC Infect Dis 11 : 304, 2011.
PubMed
6) Keane J, et al : Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345 : 1098-1104, 2001.
PubMed
7) Onishi A, et al : Diagnostic accuracy of serum 1, 3-β-D-glucan for pneumocystis jiroveci pneumonia, invasive candidiasis, and invasive aspergillosis : systematic review and meta-analysis. J Clin Microbiol 50 : 7-15, 2012.
 
8) 炎症性疾患に対する生物学的製剤と呼吸器疾患 診療の手引き 第2版 (日本呼吸器学会 炎症性疾患に対する生物学的製剤と呼吸器疾患 診療の手引き 第2版作成委員会編), 日本呼吸器学会, 2020.
 
9) 大曲貴夫 : I 総論 5 治療 1) ST合剤. ニューモシスチス肺炎のすべて (ニューモシスチス肺炎研究会編), p51, 克誠堂出版, 2014.
 
10) Nakashima K, et al : Low-dose trimethoprim-sulfamethoxazole treatment for pneumocystis pneumonia in non-human immunodeficiency virus-infected immunocompromised patients : A single-center retrospective observational cohort study. J Microbiol Immunol Infect 51 : 810-820, 2018.
PubMed
11) Hughes W, et al : Comparison of Atovaquone (566C80) with trimethoprim-Sulfamethoxazole to Treat Pneumocystis carinii Pneumonia in Patients with AIDS. N Engl J Med 328 : 1521-1527, 1993.
PubMed
12) Wallis RS, et al : Adalimumab treatment of life-threatening tuberculosis. Clin Infect Dis 48 : 1429-1432, 2009.
PubMed
13) Blackmore TK, et al : Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes. Clin Infect Dis 47 : e83-85, 2008.
PubMed
P.374 掲載の参考文献
1) McDonald JR, et al : Obstructive pneumonitis of neoplastic origin ; an interpretation of one form of so-called atelectasis and its correlation according to presence of absence of sputum. J Thorac Surg 18 : 97-112 ; disc., 122, 1949.
 
2) Esteban G, ほか : 肺癌における閉塞性肺炎の検討. 日本胸部疾患学会雑誌 30 : 1820-1824, 1992.
 
3) 宮本潤子, ほか : 原発性肺癌に合併した閉塞性肺炎の臨床的検討. 感染症学雑誌 68 : 728-733, 1994.
 
4) 小橋吉博, ほか : 肺癌に伴う閉塞性肺炎と非閉塞性肺炎の比較検討. 日本胸部臨床 55 : 913-917, 1996.
 
5) Burke M, Fraser R : Obstructive pneumonitis : a pathologic and pathogenetic reappraisal. Radiology 166 : 699-704, 1988.
PubMed
6) 宮地純樹 : リポイド肺炎. 呼吸 10 : 391-395, 1991.
Medical*Online
7) 森啓, ほか : 肺癌に合併した呼吸器感染症の予後別病態解析. 感染症学雑誌 71 : 34-38, 1997.
 
8) Liaw YS, et al : The bacteriology of obstructive pneumonitis. A prospective study using ultrasound-guided transthoracic needle aspiration. Am J Respir Crit Care Med 149 : 1648-1653, 1994.
PubMed
9) Fishman AP : Pulmonary Diseases and Disorders, 2nd ed, Vol 1, p529-566, McGraw-Hill, New York, 1988.
 
10) Bourgouin PM, et al : Differentiation of bronchogenic carcinoma from postobstructive pneumonitis by magnetic resonance imaging : Histopathologic correlation. J Thorac Imaging 6 : 22-27, 1991.
PubMed
11) 副島林造, 沖本二郎 : 肺癌患者の呼吸器感染症対策. 医学のあゆみ 157 : 567-570, 1991.
Medical*Online
12) 渡辺彰, ほか : 肺癌患者に合併する呼吸器感染症の臨床的意義. 日本胸部疾患学会雑誌 30 : 1250-1256, 1992.
 
13) 沖昌英 : 気道ステント留置術. 気管支鏡テキスト 第3版 (日本呼吸器内視鏡学会編), p323-328, 医学書院, 2019.
 
14) 朝戸裕二, 雨宮隆太 : 異物除去術. 気管支鏡テキスト 第3版 (日本呼吸器内視鏡学会編), p334-337, 医学書院, 2019.
 
P.379 掲載の参考文献
1) Fraser RG, et al : Parenchymal Atelectasis. In : Diagnosis of Diseases of the Chest, 3rd ed, vol. 1, p472-493, WB Saunders, Philadelphia, 1988.
 
2) 森田祐二, ほか : 無気肺像における気管支鏡所見の検討. 気管支学 12 : 231-238, 1990.
 
3) Tsai SL, et al : What can we learn from chest radiographs in hypoxemic asthmatics? Pediatr Radiol 32 : 498-504, 2002.
PubMed
4) Lundquist H, et al : CT-assessment of dependent lung densities in man during general anaesthesia. Acta Radiol 36 : 626-632, 1995.
PubMed
5) Canet J, et al : Prediction of postoperative pulmonary complications in a population-based surgical cohort. Anesthesiology 113 : 1338-1350, 2010.
 
6) Woodring JH, et al : Types and mechanisms of pulmonary atelectasis. J Thorac Imaging 11 : 92-108, 1996.
PubMed
7) Nishi J, et al : Pulmonary Atelectasis. In : Radiologic Diagnosis of Chest Disease, 2nd ed (ed by Sperber M), p316-332, Springer-Verlag, London, 2001.
 
8) Ashizawa K, et al : Lobar atelectasis : diagnostic pitfalls on chest radiography. Br J Radiol 74 : 89-97, 2001.
PubMed
9) Gerbaudo VH, et al : Anatomo-metabolic characteristics of atelectasis in F-18 FDG-PET/CT imaging. Eur J Radiol 64 : 401-405, 2007.
PubMed
10) Yang RM, et al : Differentiation of central lung cancer from atelectasis : comparison of diffusion-weighted MRI with PET/CT. PLoS One 8 : e60279, 2013.
PubMed
11) Schindler MB : Treatment of atelectasis : where is the evidence? Crit Care 9 : 341-342, 2005.
PubMed
P.388 掲載の参考文献
1) 免疫再構築症候群 診療のポイント Ver. 5 国立研究開発法人日本医療研究開発機構 (AMED) エイズ対策実用化研究事業「ART早期化と長期化に伴う日和見感染症への対処に関する研究」班. (研究開発分担者/発行責任 : 古西満), 2021年1月.
 
2) Wolfe C : Immune reconstitution inflammatory syndrome. UpToDate, Literature review current through : Jun 2021. This topic last updated : Aug 29, 2019.
 
3) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV : recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. [https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Adult_OI.pdf]
 
4) Shelburne SA, et al : Immune reconstitution inflammatory syndrome : more answers, more questions. J Antimicrob Chemother 57 : 167-170, 2006.
PubMed
5) Haddow LJ, et al : Defining immune reconstitution inflammatory syndrome : evaluation of expert opinion versus 2 case definitions in a South African cohort. Clin Infect Dis 49 : 1424-1432, 2009.
 
6) Murdoch DM, et al : Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa : aprospective study. AIDS 22 : 601-610, 2008.
 
7) Walker NF, et al : Immune reconstitution inflammatory syndrome in HIV-infected patients. HIV/AIDS-Research and Palliative Care 7 : 49-64, 2015.
PubMed
8) Muller M, et al : Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection : a systematic review and meta-analysis. Lancet Infect Dis 10 : 251-261, 2010.
PubMed
9) Breen RA, et al : Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection. Thorax 59 : 704-707, 2004.
PubMed
10) Meintjes G, et al : Tuberculosis-associated immune reconstitution inflammatory syndrome : case definitions for use in resource-limited settings. Lancet Infect Dis 8 : 516-523, 2008.
PubMed
11) Meintjes G, et al : Prednisone for the Prevention of Paradoxical Tuberculosis-Associated IRIS. N Engl J Med 379 : 1915-1925, 2018.
 
12) Meintjes G, et al : Management of active tuberculosis in adults with HIV. Lancet HIV 6 : e463-e474, 2019.
PubMed
13) Suryana K : A challenge in diagnosis of tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS). HIV/AIDS-Research and Palliative Care 12 : 263-269, 2020.
PubMed
14) Namale PE, et al : Paradoxical TB-IRIS in HIV-infected adults : a systematic review and meta-analysis. Future Microbiol 10 : 1077-1099, 2015.
PubMed
15) Quinn CM, et al : Tuberuculosis IRIS : Pathogenesis, presentation, and management across the spectrum of disease. Life (Basel) 10 : 262, 2020. (DOI : 10.3390/life10110262)
 
16) Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. [https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/AdultandAdolescentGL.pdf]
 

書評

最近チェックした商品履歴

Loading...